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ABSTRACT

The present disclosure relates to the synthesis ofnon-natural
analogs of S-adenosyl-L-methionine (SAM) and/or of Se
adenosyl-L-methionine (SeAM) by reacting a methionine
analog and adenosine triphosphate (ATP) in the presence of
at least one methionine adenosyltransferase (MAT), and to
use thereof with downstream SAM and/or SeAM utilizing
enzymes. The non-natural analogs of SAM and/or SeAM
have the general formula:
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where X is S or Se, and R 1 is an alkyl group.
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SYNTHESIS OF NON-NATURAL COFACTOR
ANAL OGS OF
S-ADENOSYL -L-METHIONINE USING
METHIONINE ADENOSYLTRANSFERASE
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RELATED APPLICATION
This application claims priority from U.S. Provisional
Patent Application No. 61/832,038, filed Jun. 6, 2013, the
entire disclosure of which is incorporated herein by this
reference.

10

TECHNICAL FIELD
The presently-disclosed subject matter generally relates to
the synthesis of non-natural cofactor analogs of S-adenosyl
L-methionine (SAM) and/or of Se-adenosyl-L-methionine
(SeAM) and to the various use(s) thereof.

15

INTRODUC TION

20

Methionine adenosyltransferase (MAT) is a family of
enzymes that utilizes adenosine triphosphate (ATP) and
methionine as substrates to produce S-adenosyl-L-methio
nine (SAM or AdoMet), a methyl donor in the biological
methylation of biomolecules and bioactive natural products.
(FIG. 1) [42]. The reaction occurs in an unusual two-step
mechanism in which the adenosyl group is transferred from
ATP to the sulfur atom of methionine, cleaving the triphos
phate, and the triphosphate is subsequently hydrolyzed to
PPi and Pi [45].
MAT is present in all living organisms, from bacteria to
mammals. To date, MAT structures from E. coli [40],
Thermococcus kodakarensis [48], Burkholderia pseudomallei (PDB code 3IML), Entamoeba histolytica (PDB code
3S04), Mycobacterium marinum (PDB code 3RV2), Myco
bacterium avium (PDB code 3S82), Mycobacterium tuber
culosis (PDB code 3TDE), Rattus norvegicus f36] and
Homo sapiens [50] have been solved. They are more than
50% identical to one other and share several common
features: (i) they usually appear as oligomeric proteins with
a highly conserved three-domain fold [43]; (ii) divalent
cations such as Mg2+ are required for activity and monova
lent cations such as K+ is able to enhance the reaction rate
[44]; (iii) a flexible loop suspended above the active site,
serves as a "gate" and is involved in the catalytic activity of
the enzyme [34].
Moreover, some specific analogs of SAM bearing alter
native alkyl substitution for the native methyl group have
been successfully used in vitro for the methyltransferasecatalyzed alkylation of natural products [57], DNA [58], and
proteins [59]. While these recent studies suggest M Tases
tolerate alternative SAM alkyl donors, the methods pro
posed in such studies remain impractical due to a number of
key factors. For example, previously known synthetic routes
to SAM analogs are multistep strategies that suffer from
poor overall yields and difficult purification protocols. In
addition, the corresponding SAM analogs are often highly
labile and are unable to pass through the cell membranes.
Accordingly, there is a need in the art for a simple method
of providing improved non-natural SAM analogs.

(II)

25

30
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BRIEF SUMMARY
This summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This

2

summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative fea
tures of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this summary or not. To avoid
excessive repetition, this summary does not list or suggest
all possible combinations of features.
In some embodiments, the present disclosure is directed
to the synthesis of non-natural L-methionine and/or L-sele
nomethionine analogs and to uses thereof. Accordingly, in
certain embodiments, the present disclosure provides compounds of the Formula II:

65

wherein R 1 is any alkyl group. In certain embodiments, R 1
comprises a propyl group, an ally! group, an aryl group
and/or a propargyl group. Further, in some embodiments, R 1
is selected from the group consisting of
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And in some embodiments, X is selected from the group
consisting of S and Se. In still further embodiments, R 1 is
20
selected from the group consisting of

lx� s 'v/',("°"

25

NH2
NH2
/X
�S�COOH,

30

and

� S �COOH
/X

35

NH2

and X may be S.
In some embodiments, the present disclosure is directed
to the synthesis of non-natural cofactor analogs of S-adeno
syl-L-methionine (SAM) and/or Se-adenosyl-L-methionine 40
(SeAM) using methionine adenosyltransferase and to uses of
the non-natural SAM and/or SeAM analogs. Accordingly, in
some embodiments, the present disclosure provides a SAM
analog and/or a SeAM analog of the Formula I:
45
(I)

50

Likewise, the present disclosure provides, in some
embodiments, methods of producing an indolocarbazole
analog. Such methods comprise the step of reacting a first
substrate with a second substrate in the presence of a
methionine adenosyltransferase (MAT).
In some embodiments of the methods provided herein, the
first substrate comprises a compound according to Formula
II, the second substrate comprises adenosine triphosphate
(ATP) and/or the MAT comprises at least one of human
MAT II catalytic alpha and regulatory beta subunit
(hMAT2), human MAT II catalytic alpha subunit alone
(hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol
fataricus MAT (sMAT), and Methanocaldococcus jannaschii MAT (mMAT). Additionally, the present disclosure
provides that any of the methods described herein may be
conducted in one pot, i.e., in a single vessel.
The present disclosure further presents a method for
production of a chemical library, the method comprising at
least the step of reacting a plurality of compounds according
to Formula II with ATP in the presence of at least one MAT
to obtain at least one non-natural compound. In some
embodiments, the at least one non-natural compound is a
SAM analog and/or a SeAM analog.
Furthermore, the present disclosure also provides, in
certain embodiments, a method of producing a SAM analog
by reacting a first substrate comprising methionine-tetrazole
with a second substrate in the presence of at least one
methionine adenosyltransferase (MAT). Moreover, in some
embodiments, the second substrate comprises ATP. And in
some embodiments, the MAT comprises at least one of
human MAT II catalytic alpha and regulatory beta subunit
(hMAT2), human MAT II catalytic alpha subunit alone
(hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol
fataricus MAT (sMAT), and Methanocaldococcus janna
schii MAT (mMAT).
In some embodiments, the present disclosure provides a
method for producing a natural product analog, comprising:
(i) reacting a methionine analog and at least one methionine
adenosyltransferase to produce an S-adenosyl-L-methionine
analog in a vessel; (ii) providing at least one methyl trans
ferase and at least one natural product in the vessel; and (iii)
alkylating the natural product in the presence of the methyl
transferase and the S-adenosyl-L-methionine analog to pro
duce a natural product analog in the vessel. In some embodi
ments, the methionine analog is a compound according to
Formula II, as described herein. And in certain embodi
ments, S-adenosyl-L-homocysteine hydrolase is also provided in the vessel.
DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a reaction catalyzed by MAT.
FIG. 2 shows representative methylated natural products
where methyl groups deriving from SAM via MT-catalyzed
methylation are highlighted as spheres. AT3 (AT2433); CLC
(colchicine); ESP (esperamicin); EVM (evemimicin); GLM
wherein R is a compound according to Formula II and
(geldamycin); MGM (megalomicin); and NGM (nogalamywherein R is attached through an S or Se atom and/or
through the X atom. In certain embodiments, R comprises 60 cin) are presented.
FIG. 3 provides a methionine adenosyltransferase (MAT)
methionine-tetrazole.
catalyzed reaction, where L-Met (R=CH3, X=S) is the
Further, the present disclosure also provides, in certain
native substrate leading to native product S-adenosylmethio
embodiments, methods of producing an S-adenosyl-L-me
nine (R=CH3, X=S). The variability of both R and X is
thionine analog and/or a Se-adenosyl-L-methionine (SeAM)
analog, comprising at least the step of reacting a first 65 described within the present disclosure.
FIG. 4 presents the general methodology for the synthesis
substrate with a second substrate in the presence of a
of S- and Se-L-Met analogs (X=S and Se, respectively) (i)
methionine adenosyltransferase (MAT).
55

5
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Na, NH3 , -78° C. with 1 or 1-Se; (ii) K2C03, acetone with
1-Hcy; (iii) NaBH4/NaOH, H20, THF, 5 h with 1-Se; (iv)
HCl, Reflux with 2-Se (see Table 1).
FIG. 5 illustrates the turnover of S/Se-Met analogs to the
corresponding S(Se)AM analogs catalyzed by selected
MATs based upon reverse phase high performance liquid
chromatography (RP-HPLC) (average percent errors5%).
Notably, no product formation was observed in the absence
of MAT, S/Se-Met analogs or ATP.
FIG. 6 provides the structures of the S/Se-Met analogs
listed in FIG. 5 (X=S, Se).
FIG. 7 presents mapping of residue positions that differ
among eMAT (Protein Data Bank (PDB) ID:1RG9),
hMAT2A (PDB ID:2P02) and hMATlA (PDB ID:20BV)
on the hMAT2A homodimeric structure. Conserved residues
among all three MATs are indicated by grey ribbons; resi
dues that differ among all three MATs are highlighted as ball
and stick models; and conserved residues among 'stringent'
MATs (hMATlA and eMAT) which differ from the more
permissive hMAT2A are highlighted by lighter-colored ball
and stick models.
FIG. 8 provides the products of hMAT2A-RebM coupled
reaction in the presence of 3/3-Se, 7/7-Se, 4/4-Se, and 6/6-Se
(see FIG. 5, FIG. 6). The percent product formation is noted
in parentheses based upon the S/Se-Met analogs utilized
(average percent errors5%).
FIG. 9 shows the synthesis of S/Se-alkylated L-methio
nine analogs, when "a" is NaN3 , nBu4NHS04, NaHC03
(sat)/CH2Cl2;
FIG. 10 shows the synthesis of S/Se-alkylated L-methionine analogs, when "b" is Na, NH3, -78° C.
FIG. 11 shows the synthesis of S/Se-alkylated L-methio
nine analogs, when "c" is K2C03, acetone.
FIG. 12 shows the synthesis of S/Se-alkylated L-methio
nine analogs, when "b" is Na, NH3, -78° C.
FIG. 13 shows the synthesis of S/Se-alkylated L-methio
nine analogs, when "d" is NaBHiNaOH, H20, THF, rt
(room temperature), 5 h.
FIG. 14 shows the synthesis of S/Se-alkylated L-methio
nine analogs, when "e" is HCl, reflux.
FIG. 15 provides high performance liquid chromatogra
phy (HPLC) traces for representative reactions. The first
column (left/bottom) provides representative reactions
(Method D) catalyzed by hMAT2 illustrating the production
of Se-SAM analogs (denoted by a black dot) in the presence
of a select set of L-SeMet analogs. Starting material (ATP)
is designated by a star. The second column (middle) pro
vides representative reactions (Method D) catalyzed by
hMAT2 illustrating the production of SAM analogs (denoted
by a black dot) and/or 5'-methyl-thio-5'-deoxyadenosine
(MTA, designated by a 'X') in the presence of a select set
ofL-Met analogs. Starting material (ATP) is designated by a
star and the SAM degradation product, adenine, is labeled
with an 'A'. The third column (right/top) provides represen
tative hMAT /RebM coupled reactions (Method E) where the
peaks corresponding to differentially alkylated products are
highlighted by the black dot and peaks at 'S' and 'M'
correspond to the remaining substrate and methylated prod
ucts, respectively. A small amount of methylated product is
formed in the control lacking L-MetlL-Met analog (bottom
panel), suggesting purified hMAT2 and/or RebM retains a
small amount of residual L-Met and/or SAM. For all chro
matograms illustrated, numbers within each correspond to
the Se-Met or S-Met analogs utilized.
FIG.16 illustrates the turnover of S/Se-Met analogs to the
corresponding S(Se)AM analogs catalyzed by sMAT based
upon RP-HPLC (average percent errors5%, see Table 4).
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Light-colored bars (referring to branched L-alkyl-substi
tuted analogs) denote analogs for which only trace turnover
was observed with MATs studied to date. As controls, no
product formation was observed in the absence of sMAT,
S/Se-Met analogs or ATP.
FIG. 17 provides HPLC traces for representative sMAT
reactions illustrating the production of SAM analogs and/or
5'-methyl-thio(seleno)-5'-deoxyadenosine (MTA) in the
presence of a select set of L-Met analogs. Starting material
(ATP) is designated by a dot.
FIG. 18 shows an example of a synthesis of (seleno)
methionine analogs, high-throughput MAT assay, and prod
uct verification via LC/MS.
FIG. 19 illustrates a reaction catalyzed by MAT.
FIG. 20 presents the synthesis of methionine tetrazole
(T-met), where: (a) is (Boc)20, pyridine, NH4HC03 , rt, 5 h,
70-8-%; (b) is (TFA)20: pyridine (1:1), THF, 0° C., 3 h,
85-95%; (c) is NaN3 , ZnBr2, H20/2-propanol (2:1), 80° C.,
16 h, 80-90%; and (d) is Et2NH, CH2Cl2, 0.5 h, 80-94%.
FIG. 21 provides data illustrating the stability of SAM- T
relative to native SAM.
DETAILED DESCRIPTION OF EXEMPLARY
EMBODIMEN TS
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The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exem
plary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
Each example is provided by way of explanation of the
present disclosure and is not a limitation thereon. In fact, it
will be apparent to those skilled in the art that various
modifications and variations can be made to the teachings of
the present disclosure without departing from the scope of
the disclosure. For instance, features illustrated or described
as part of one embodiment can be used with another embodiment to yield a still further embodiment.
All references to singular characteristics or limitations of
the present disclosure shall include the corresponding plural
characteristic(s) or limitation(s) and vice versa, unless oth
erwise specified or clearly implied to the contrary by the
context in which the reference is made.
The methods and compositions of the present disclosure,
including components thereof, can comprise, consist of, or
consist essentially of the essential elements and limitations
of the embodiments described herein, as well as any addi
tional or optional components or limitations described
herein or otherwise useful.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, some defini
tions are set forth to facilitate explanation of the presently
disclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.

US 9,879,043 Bl
7

Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, refer
ence to "a fluorophore" includes a plurality of such images,
and so forth.
Unless otherwise indicated, all numbers expressing quan
tities, properties, and so forth used in the specification and
claims are to be understood as being modified in all
instances by the term "about". Accordingly, unless indicated
to the contrary, the numerical parameters set forth in this
specification and claims are approximations that can vary
depending upon the desired properties sought to be obtained
by the presently-disclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass varia
tions of in some embodiments ±50%, in some embodiments
±40%, in some embodiments ±30%, in some embodiments
±20%, in some embodiments ± 10%, in some embodiments
±5%, in some embodiments ±1%, in some embodiments
±0.5%, and in some embodiments ±0.1% from the specified
amount, as such variations are appropriate to perform the
disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
With regard to alkyl substituents, the term "alkyl" refers
to alkyl groups with the general formula CnH2n+1 ' where n
is in the range of about 1 to about 18 or more. The groups
can be straight-chained or branched. Alkyl, when used
herein, also comprises "lower alkyls," which refer to alkyl
groups with the general formula CnH2n+ i, where n is in the
range of about 1 to about 6. In some embodiments, n is about
1 to about 3. Examples include methyl, ethyl, propyl,
isopropyl, n-butyl, sec-butyl, t-butyl, isobutyl, n-pentyl,
isopentyl, neopentyl, n-hexyl, and the like. Throughout the
specification "alkyl" is generally used to refer to both
unsubstituted alkyl groups and substituted alkyl groups, and
this practice holds true for the other groups (e.g., cycloalkyl,
etc.) described herein.
The term "aryl" as used herein is a group that contains any
carbon-based aromatic group including, but not limited to,
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene,
and the like. The term "aryl" also includes bi aryls (e.g.,
naphthalene or biphenyl) or "heteroaryl," which is defined
as a group that contains an aromatic group that has at least
one heteroatom incorporated within the ring of the aromatic
group. Examples of heteroatoms include, but are not limited
to, nitrogen, oxygen, sulfur, and phosphorus. Likewise, the
term "non-heteroaryl," which is also included in the term
"aryl," defines a group that contains an aromatic group that
does not contain a heteroatom. The aryl group can be
substituted or unsubstituted. The aryl group can be substituted with one or more groups including, but not limited to,
optionally substituted alkyl, cycloalkyl, alkoxy, alkenyl,
cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, alde
hyde, amino, carboxylic acid, ester, ether, halide, hydroxy,
ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described
herein. The term "thiol" as used herein is represented by a
formula -SH.
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The term "substrate" means a substance that is acted upon
by an enzyme in a chemical reaction.
As used herein, the term "substituted" is contemplated to
include all permissible substituents of organic compounds.
In a broad aspect, the permissible substituents include acy
clic and cyclic, branched and unbranched, carbocyclic and
heterocyclic, and aromatic and nonaromatic substituents of
organic compounds, peptides, lipids, oligonucleotides, and
oligosaccharides. Illustrative substituents include, for
example, those described herein. The permissible substitu
ents can be one or more and the same or different for
appropriate organic compounds. For purposes of this dis
closure, cobalamin may comprise alkyl substituents and/or
any permissible substituents of organic compounds
described herein, including those that induce strain in the
embodied compounds. This disclosure is not intended to be
limited in any manner by the permissible substituents of
organic compounds.
Notably, throughout the present disclosure, various
embodiments of the methods and compositions provided
herein are described in the written examples and in the
drawings. In these examples and drawings, some specific
structures are labeled with numbers (e.g., 1, 2, 3, etc.) to
refer to the structures. For example, FIG. 8 includes distinct
structures/compounds labeled as 31, 32, 33, 32, and 35,
respectively.
The presently-disclosed subject matter further includes
pharmaceutical compositions comprising compounds as dis
closed herein. Such pharmaceutical compositions may comprise at least one pharmaceutically-acceptable carrier. In this
regard, the term "pharmaceutically acceptable carrier" refers
to sterile aqueous or non-aqueous solutions, dispersions,
suspensions or emulsions, as well as sterile powders for
reconstitution into sterile injectable solutions or dispersions
just prior to use. Proper fluidity can be maintained, for
example, by the use of coating materials such as lecithin, by
the maintenance of the required particle size in the case of
dispersions and by the use of surfactants. These composi
tions can also contain adjuvants such as preservatives,
wetting agents, emulsifying agents and dispersing agents.
Prevention of the action of microorganisms can be ensured
by the inclusion of various antibacterial and antifungal
agents such as paraben, chlorobutanol, phenol, sorbic acid
and the like. It can also be desirable to include isotonic
agents such as sugars, sodium chloride and the like. Pro
longed absorption of the injectable pharmaceutical form can
be brought about by the inclusion of agents, such as alumi
num monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the
nature of the particular polymer employed, the rate of drug
release can be controlled. Depot injectable formulations are
also prepared by entrapping the drug in liposomes or micro
emulsions, which are compatible with body tissues. The
injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorpo
rating sterilizing agents in the form of sterile solid compo
sitions which can be dissolved or dispersed in sterile water
or other sterile injectable media just prior to use. Suitable
inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants,
buffers, bacteriostats, bactericidal antibiotics and solutes
that render the formulation isotonic with the bodily fluids of
the intended recipient; and aqueous and non-aqueous sterile
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suspensions, which can include suspending agents and
thickening agents. Moreover, the compositions can take
such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and can contain formulatory agents such
as suspending, stabilizing and/or dispersing agents. Alter
natively, the active ingredient can be in powder form for
constitution with a suitable vehicle, e.g., sterile pyrogen-free
water, before use. The formulations can be presented in
unit-dose or multi-dose containers, for example sealed
ampoules and vials, and can be stored in a frozen or
freeze-dried (lyophilized) condition requiring only the addi
tion of sterile liquid carrier immediately prior to use.
The presently-disclosed subject matter further includes a
kit that can include a compound or pharmaceutical compo
sition as described herein, packaged together with a device
useful for administration of the compound or composition.
As will be recognized by those or ordinary skill in the art,
the appropriate administration-aiding device will depend on
the formulation of the compound or composition that is
selected and/or the desired administration site/method. For
example, if the formulation of the compound or composition
is appropriate for injection in a subject, the device could be
a syringe. For another example, if the desired administration
site is cell culture media, the device could be a sterile
pipette.
Still further, the presently-disclosed subject matter
includes a method for treating disease(s), such as cancer. In
some embodiments, the method comprises administering a
compound, including one of the compounds described
herein, to an administration site of a subject in need thereof.
The term "administering" refers to any method of pro
viding a compound and/or pharmaceutical composition
thereof to a subject. Such methods are well known to those
skilled in the art and include, but are not limited to, oral
administration, transdermal administration, administration
by inhalation, nasal administration, topical administration,
intravaginal administration, ophthalmic administration,
intraaural administration, intracerebral administration, rectal
administration, and parenteral administration, including
injectable such as intravenous administration, intra-arterial
administration, intramuscular administration, and subcuta
neous administration. Administration can be continuous or
intermittent. In various aspects, a preparation can be admin
istered therapeutically; that is, administered to treat an
existing disease or condition (e.g., cancer, tumors, etc.). In
further various aspects, a preparation can be administered
prophylactically; that is, administered for prevention of a
disease or condition.
In some embodiments, a subject will be administered an
effective amount of the compound. In this respect, the term
"effective amount" refers to an amount that is sufficient to
achieve the desired result or to have an effect on an unde
sired condition. For example, a "therapeutically effective
amount" refers to an amount that is sufficient to achieve the
desired therapeutic result or to have an effect on undesired
symptoms, but is generally insufficient to cause adverse side
effects. The specific therapeutically effective dose level for
any particular patient will depend upon a variety of factors
including the disorder being treated and the severity of the
disorder; the specific composition employed; the age, body
weight, general health, sex and diet of the patient; the time
of administration; the route of administration; the rate of
excretion of the specific compound employed; the duration
of the treatment; drugs used in combination or coincidental
with the specific compound employed and like factors well
known in the medical arts. For example, it is well within the
skill of the art to start doses of a compound at levels lower
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than those required to achieve the desired therapeutic effect
and to gradually increase the dosage until the desired effect
is achieved. If desired, the effective daily dose can be
divided into multiple doses for purposes of administration.
Consequently, single dose compositions can contain such
amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in
the event of any contraindications. Dosage can vary, and can
be administered in one or more dose administrations daily,
for one or several days. Guidance can be found in the
literature for appropriate dosages for given classes of phar
maceutical products. In further various aspects, a prepara
tion can be administered in a "prophylactically effective
amount"; that is, an amount effective for prevention of a
disease or condition.
Additionally, the terms "subject" or "subject in need
thereof' refer to a target of administration, which optionally
displays symptoms related to a particular disease, pathologi
cal condition, disorder, or the like. The subject of the herein
disclosed methods can be a vertebrate, such as a manmial, a
fish, a bird, a reptile, or an amphibian. Thus, the subject of
the herein disclosed methods can be a human, non-human
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea
pig or rodent. The term does not denote a particular age or
sex. Thus, adult and newborn subjects, as well as fetuses,
whether male or female, are intended to be covered. A
patient refers to a subject afflicted with a disease or disorder.
The term "subject" includes human and veterinary subjects.
The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a disease, pathological condition, or
disorder. This term includes active treatment, that is, treat
ment directed specifically toward the improvement of a
disease, pathological condition, or disorder, and also
includes causal treatment, that is, treatment directed toward
removal of the cause of the associated disease, pathological
condition, or disorder. In addition, this term includes pal
liative treatment, that is, treatment designed for the relief of
symptoms rather than the curing of the disease, pathological
condition, or disorder; preventative treatment, that is, treat
ment directed to minimizing or partially or completely
inhibiting the development of the associated disease, patho
logical condition, or disorder; and supportive treatment, that
is, treatment employed to supplement another specific
therapy directed toward the improvement of the associated
disease, pathological condition, or disorder.
Moreover, in some embodiments, the present disclosure
provides a novel chemoenzymatic alternative for the syn
thesis of SAM and/or SeAM analogs. Certain embodiments
of the subject matter of the present disclosure are related to
methionine analog synthesis to provide substrates for a
range of permissive methionine adenosyltransferases
(MATs). Further embodiments of the present disclosure
include analogs of S-adenosyl-1-methionine. Still further
embodiments of the present disclosure include analogs of
Se-adenosyl-L-methionine. And various embodiments of the
present disclosure are advantageous at least because they
circumvent liabilities of the existing state of the art.
One embodiment of the subject matter of the present
disclosure is a chemoenzymatic synthesis of SAM analogs
and/or SeAM analogs. In some embodiments, the present
disclosure provides methods of reacting S/Se-Met analogs
with methyl transferases to produce SAM and/or SeAM
analogs. In certain methods of the present disclosure, 2:about
20% turnover from S/Se-Met analog(s) to SAM/SeAM
analog(s) is achieved. And in other embodiments, 2:about
10%, and/or 2:about 30%, and/or 2:about 40% and/or 2:about
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50% turnover from S/Se-Met analog(s) to SAM and/or
SeAM analog(s) is achieved in the presently disclosed
methods.
Embodiments of the subject matter of the present disclo
sure also present the ability to directly couple SAM and/or
SeAM synthesis with downstream MTase utilization in a
one-pot reaction. As such, one embodiment of the subject
matter of the present disclosure is a process using MAT to
produce SAM and/or SeAM analogs.
An additional advantage of this approach is the permeability of cells to methionine, suggesting the novel potential
for intracellular SAM and/or SeAM analog synthesis as
enabling technology for a broad range of chemical and/or
biological applications.
In some embodiments, the present disclosure is directed
to the synthesis of L-methionine and/or L-selenomethionine
analogs, including non-natural and/or synthetic analogs, and
to uses thereof. Indeed, in certain embodiments, the disclo
sure provides compounds of the Formula II:
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wherein X is S.
Additionally, the present disclosure is directed to the
synthesis of cofactor analogs of S-adenosyl-L-methionine
and/or Se-adenosyl-L-methionine using methionine adeno
syltransferase, such as non-natural and/or synthetic analogs,
and to uses thereof.
Accordingly, in some embodiments, the present disclo
sure provides an S-adenosyl-L-methionine (SAM) and/or an
Se-adenosyl-L-methionine (SeAM) analog of the Formula I:
(I)

N3

,

l s �·lx�·

/xD

and X is selected from the group consisting of S and Se.
In some embodiments, R1 is selected from the group
consisting of

/s �N,
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wherein R comprises a compound according to Formula II
and wherein R is attached through an S or Se atom and/or
through the X atom. And in certain embodiments, R com
prises methionine-tetrazole.
The present disclosure also provides, in certain embodiments, methods of producing a SAM analog and/or a SeAM
analog, comprising at least the step of reacting a first
substrate with a second substrate in the presence of a
methionine adenosyltransferase (MAT). Additionally, the
present disclosure provides, in some embodiments, methods
of producing an indolocarbazole analog. Such methods
comprise the step of reacting a first substrate with a second
substrate in the presence of a methionine adenosyltrans
ferase (MAT).
In some embodiments, the first substrate comprises a
compound according to Formula II, the second substrate
comprises adenosine triphosphate (ATP) and/or the MAT
comprises at least one of human MAT II catalytic alpha and
regulatory beta subunit (hMAT2), human MAT II catalytic
alpha subunit alone (hMAT2A), human MAT I catalytic
subunit alpha (hMATlA), Escherichia coli MAT (eMAT),
Sulfolobus solfataricus MAT (sMAT), and Methanocaldo
coccus jannaschii MAT (mMAT). Additionally, the present
disclosure provides that any of the methods described herein
may be conducted one pot, i.e., a single vessel. The terms
"vessel", "pot" and "container" are used interchangeably in
the present disclosure.
The present disclosure further presents a method for
production of a chemical library, the method comprising the
step of reacting a plurality of compounds according to
Formula II with ATP in the presence of at least one MAT to
obtain at least one synthesized compound. In some embodi
ments, the at least one synthesized compound is a SAM
analog and/or a SeAM analog. Furthermore, the present
disclosure also provides, in certain embodiments, a method
of producing at least one SAM analog and/or at least one
SeAM analog. The method comprises the step of reacting a
first substrate comprising methionine-tetrazole with a sec
ond substrate in the presence of at least one methionine
adenosyltransferase (MAT). Moreover, in some embodiments, the second substrate comprises ATP and/or the MAT
comprises at least one of human MAT II catalytic alpha and
regulatory beta subunit (hMAT2), human MAT II catalytic
alpha subunit alone (hMAT2A), human MAT I catalytic
subunit alpha (hMATlA), Escherichia coli MAT (eMAT),
Sulfolobus solfataricus MAT (sMAT), and Methanocaldo
coccus jannaschii MAT (mMAT).
And in some embodiments, the present disclosure pro
vides a method for producing a natural product analog,
comprising: (i) reacting a methionine analog and at least one
methionine adenosyltransferase to produce a SAM analog
and/or a SeAM analog in a vessel; (ii) providing at least one
methyl transferase and at least one natural product in the
vessel; and (iii) alkylating the natural product in the pres
ence of the methyl transferase and the SAM analog and/or
the SeAM analog to produce a natural product analog in the
vessel. In some embodiments, the methionine analog is a
compound according to Formula II, as described herein
above.
Similarly, the present disclosure provides a method for
alkylating at least one drug, at least one molecule of DNA
and/or at least one protein, the method comprising (i)
reacting a methionine analog and at least one methionine
adenosyltransferase to produce a SAM analog and/or a
SeAM analog in a vessel; (ii) providing at least one methyl
transferase and at least one drug, at least one molecule of
DNA and/or at least one protein in the vessel; and (iii)
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alkylating the at least one drug, at least one molecule of
DNA and/or at least one protein to produce a drug analog,
a DNA analog and/or a protein analog in the vessel.
5

10

And in certain embodiments, S-adenosyl-L-homocysteine
hydrolase (SAH-hdyrolase) is provided in the vessel. It is
believed that inclusion of SAH-hydrolase (SAHH) in the
coupled reaction may prevent product inhibition associated
with most if not all methyltransferases.
In some embodiments, the present disclosure provides an
S-adenosyl-L-methionine (SAM) or Se-adenosyl-L-methio
nine (SeAM) analog of the Formula III:
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(eMAT), Sulfolobus solfataricus MAT (sMAT), and Metha
nocaldococcus jannaschii MAT (mMAT).
In some embodiments of the methods of the present
disclosure, the first substrate is a compound of the Formula
II:

N02; and

wherein, when X 1s Se, R1 1s selected from the group
consisting of:

(II)
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wherein R1 is selected from the group consisting of
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In some embodiments, the present disclosure provides an
S-adenosyl-L-methionine analog of the Formula I:
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wherein R is a compound according to Formula II and R is
NH2,
attached through an S atom.
55 lx�N3,
l se�
In some embodiments, the present disclosure provides a
method of producing an S-adenosyl-L-methionine analog or
an S-adenosyl-L-methionine analog of the present disclo
Is
sure, comprising the step of reacting a first substrate com
prising a methionine analog with a second substrate in the 60
�
presence of a methionine adenosyltransferase (MAT). In
some embodiments, the second substrate comprises adenos
ine triphosphate (ATP), and in certain embodiments, the
MAT comprises at least one of human MAT II catalytic
IS
alpha and regulatory beta subunit (hMAT2), human MAT II 65
� M<<
catalytic alpha subunit alone (hMAT2A), human MAT I
catalytic subunit alpha (hMATlA), Escherichia coli MAT
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wherein X is selected from the group consisting of S and Se.

10
Further, in some embodiments, the present disclosure
provides a method of producing an indolocarbazole analog,
comprising the step of reacting a first substrate comprising
a methionine analog with a second substrate in the presence
of a methionine adenosyltransferase (MAT), wherein the 15
methionine analog is a compound of the Formula II:
(II)

wherein R1 is selected from the group consisting of

/(� Ix � ls --c,.
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N,

,

l x �.l x �,
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and

and wherein X is selected from the group consisting of S and
20 Se. In some embodiments, the second substrate comprises at
least one indolocarbazole group. And in some embodiments,
the MAT comprises at least one of human MAT II catalytic
alpha and regulatory beta subunit (hMAT2), human MAT II
catalytic alpha subunit alone (hMAT2A), human MAT I
catalytic subunit alpha (hMATlA), Escherichia coli MAT
25
(eMAT), Sulfolobus solfataricus MAT (sMAT), and Metha
nocaldococcus jannaschii MAT (mMAT).
Moreover, in some embodiments, the present disclosure
provides a method for producing a natural product analog,
comprising: (i) reacting a methionine analog and at least one
30 methionine adenosyltransferase to produce an S-adenosyl
L-methionine analog and/or an Se-adenosyl-L-methionine
analog of the present disclosure in a vessel; (ii) providing at
least one methyl transferase and a natural product in the
vessel; and (iii) alkylating the natural product in the pres35 ence of the methyl transferase and the S-adenosyl-L-me
thionine analog and/or Se-adenosyl-L-methionine analog to
produce a natural product analog in the vessel. In some
embodiments of this method, the methionine analog is a
compound of the Formula II:
40
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and wherein X is selected from the group consisting of S and
Se.
The present disclosure profiles a range of MATs to iden
tify MAT(s) that turn over a wide range of methionine
analogs to the corresponding SAM and/or SeAM analogs.
Further, the present disclosure demonstrates that a MAT
reaction can be coupled in a single pot to generate differ
ential alkylation. This enzymatic platform for differential
alkylation (alkylrandomization) is an improvement over the
existing prior art.
As indicated herein, in some embodiments, the subject
matter of the present disclosure is directed to the synthesis
of differentially alkylated analogs. Another embodiment
provides a process of combining a library of differentially
alkylated analogs with a promiscuous methionine adenosyl
transferase to afford the synthesis of differentially alkylated
SAM and/or SeAM analogs. In certain embodiments, the
present disclosure is directed to a method for producing a
chemical library, comprising reacting a plurality of L-me
thionine and/or L-selenomethionine analogs with ATP in the
presence of at least one MAT to obtain a plurality of SAM
and/or SeAM analogs.
Another embodiment of the subject matter of the present
disclosure is a process of the compounds of the present
disclosure with promiscuous methyltransferases to afford
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differential alkylation of drugs and natural products. A
further embodiment of the subject matter of the present
disclosure provides differentially alkylated SAM and/or
SeAM analogs. Yet another embodiment of the subject
matter of the present disclosure provides SAM and/or SeAM
analogs bearing reactive functional groups as reagents for
cell biology/epigenetics.
And a further embodiment of the subject matter of the
present disclosure is the process of feeding said analogs
(bearing reactive functional groups) to afford the above in a
cell-based format (versus crude extracts which is the current
state of the art). Additionally, the subject matter of the
present disclosure provides a platform for MAT engineering
and evolution, a coupled MAT-MTase platform for natural
product alkylrandomization, and a platform for MTase engi
neering and evolution.
One of ordinary skill in the art would readily recognize
that embodiments of the subject matter of the present
disclosure provide robust combinatorial methods for the
synthesis of methionine analogs.
Moreover, the ability to couple SAM synthesis and utili
zation in a single vessel circumvents issues associated with
rapid SAM analog decomposition.
EXAMPLES
The presently-disclosed subject matter is further illus
trated by the following specific but non-limiting examples.
The examples may include compilations of data that are
representative of data gathered at various times during the
course of development and experimentation related to the
presently-disclosed subject matter.
Example I
Chemoenzymatic Synthesis of SAM Analogs:
This example highlights a broadly applicable platform for
the syntheses of SAM analogs that is directly compatible
with downstream SAM utilizing enzymes. The ability to
couple SAM synthesis and utilization in a single vessel
circumvents issues associated with rapid SAM analog
decomposition and thereby opens the door to the further
interrogation of a wide range of SAM utilizing enzymes. As
a proof of concept for the feasibility of natural product
'alkylrandomization', the coupled strategy was used to gen
erate a small set of indolocarbazole analogs in conjunction
with the rebeccamycin 0-methyltransferase RebM.
Enzyme-catalyzed late stage group transfer-based tailor
ing reactions contribute to the structural and functional
diversity of many complex natural products (NPs).[1] Rep
resentative examples include amination, acylation, alky
lation, glycosylation, halogenation, phosphorylation and
sulfation and, in some cases, enzymes responsible for such
transformations display notable flexibility with respect to
their substrate scope. [2] Such promiscuity is an enabling
feature of chemoenzymatic NP diversification platforms as
exemplified by NP glycorandomization (a platform for dif
ferential glycosylation of natural products/drugs).[3] Among
the examples above, enzyme-catalyzed alkylation is a highly
prevalent occurrence that leads to NP N-, 0-, S- and/or
C-alkylation (FIG. 2).[4] Thus, a platform to co-opt natural
product methyltransferases (M Ts) for broad natural product
differential alkylation (alkylrandomization) will dramatically expand the potential scope of NP chemical diversity.
The typical alkyl donor for MT-catalyzed alkylation is
S-adenosyl-L-methionine (SAM) and importantly, the pres
ent inventors have demonstrated NP [5], protein, [6] and
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nucleic acid [7] MTs to transfer alternative alkyl groups in
the presence of suitably modified SAM analogs. However,
reminiscent of the restriction imposed upon glycorandom
ization by sugar nucleotide availability, access to stable
SAM analog arrays similarly restricts NP alkylrandomization development.
Current state-of-art for SAM analog chemical synthesis
relies upon multi-step syntheses of diastereomeric SAM
analog mixtures and requires HPLC purification to remove
starting material, S-adenosyl-homocysteine (SAH, a strong
inhibitor of MTs). [8] The desired purified SAM analogs
from this process are also markedly unstable, thereby lim
iting their practical development as standalone synthetic
reagents and/or biological probes. Within this context, a
general platform to enable the generation and direct utilization of SAM analogs, beginning from stable precursors,
would be considered advantageous.
To address this need, herein a broad substrate specificity
assessment ofa representative set offive distinct methionine
adenosyltransferases (MATs) from various sources is
described. MAT (EC 2.5.1.6; also sometimes referred to as
AdoMet synthetase or SAM synthetase) is the primary
catalyst used for the biosynthesis of SAM from adenine
triphosphate (ATP) and L-methionine (Met) (FIG. 1, FIG. 2)
and there is preliminary evidence to suggest certain MATs to
be capable ofMet analog utilization. [6e, 9] Consistent with
this notion, the studies highlighted herein reveal human
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MAT II (hMAT2) to enable the cumulative synthesis of a
broad panel ofunnatural SAM analogs (29 analogs detected)
starting from synthetic S/Se-alkylated Met analogs (44 ana
logs) or commercial sources (3 analogs).
To demonstrate the feasibility of NP alkylrandomization,
this study also highlights the subsequent generation of a
small set of indolocarbazole analogs using a coupled
hMAT2-RebM system, where RebM is the sugar C4'-0-MT
involved in rebeccamycin biosynthesis. [5a, 10] This study
offers both a strategic advance in terms ofNP diversification
and reveals hMAT2 to display surprising permissivity.
Given the conflicting reports regarding the relative sta
bility of S- versus Se-SAM [6c, 6d, 11] and the fact that
Se-SAM is considered a better alkyl donor than S-SAM in
MT-catalyzed reactions due to the inherently longer and
weaker Se----C bond, [11b] both S- and Se-Met analogs were
synthesized for this study. The general strategy for the
synthesis ofthe S- and Se-Met analog panel employed direct
or reductive alkylation ofthe corresponding L-homocysteine
dimer (1 or 1-Se, FIG. 4 i and iii, respectively), L-Hcy (FIG.
4, ii) or 2-Se (FIG. 4, iv) following modifications ofreported
strategies. [12] The desired S- and Se-Met analogs were
purified from crude reaction mixtures by reverse phase high
pressure liquid chromatography (RP-HPLC), C 18 RP flash
chromatography or Dowex 50W8X-200 resin to afford iso
lated yields ranging from 20-90% (see Table 1).

TABLE 1
Swnmary of synthesized L-methionine and L-selenomethionine analogs
Method

Method
Code

Compound

1, 1-Se

S-alkyl Se-alkyl Code
c.a.[a]

ref [25] 16

c .a. [a]

c.a. [a] 17

S-alkyl Se-alkyl

Compound

FIG. 10

n.a.[b]

FIG. 10

n.a.[bJ

FIG. 10

n.a.[bJ

/ ,, X
COOH
x
�
NH2

2, 2-Se

NH2

ls�

HOOC� X /

3, 3-Se

N3

FIG. 10 FIG. 12 18
Is�

4, 4-Se

FIG. 10 FIG. 12 19, 19-Se

FIG. 10

6, 6-Se

n.a.[bJ 20, 20-Se

FIG. 11 FIG. 13 21

Ix�

1xD

FIG. 10 FIG. 13

FIG. 11 FIG. 13

FIG. 10

n.a.[bJ

1S� N3
7, 7-Se

FIG. 11 FIG. 12 22, 22-Se

FIG. 10 FIG. 14
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TABLE I-continued
Summary of synthesized L-methionine and L-selenomethionine analogs

Method
Code

Compound

FIG. 10 FIG. 13 23, 23-Se

9, 9-Se

FIG. 10 FIG. 14 24-Se

10, 10-Se

FIG. 10 FIG. 13 25

Is �

12, 12-Se

Compound

S-alkyl Se-alkyl Code

8, 8-Se

11

Method

FIG. 10

FIG. 10 FIG. 12

Is

n.a.[bJ 26

Is

Ix�

n.a.[bJ

FIG. 13

FIG. 10

n.a.[bJ

FIG. 10

n.a.[bJ

�

�

FIG. 10 FIG. 12 27, 27-Se

FIG. 11 FIG. 13

;(�
13, 13-Se

S-alkyl Se-alkyl

!x�No,

OOH
l s � s 'v-"'
(

FIG. 10 FIG. 13 28

FIG. 10

n.a.[bJ

FIG. 10

n.a.[bJ

FIG. 10

n.a.[bJ

NH2

14

FIG. 10

15, 15-Se

FIG. 10 FIG. 13 30

NH2

l s � s �COOH

n.a.[bJ 29

[ale.a.: commercially available;
[bln.a.: not available.

A representative set of MATs from variant sources,
including bacterial, archaeal and manmialian orthologs,
were selected for the initial assessment. Specifically, the
exploratory set included human MAT II catalytic alpha and
regulatory beta subunit (hMAT2), [13] human MAT II
catalytic alpha subunit alone (hMAT2A), [13] human MAT
I catalytic subunit alpha (hMATlA),[13] Escherichia coli
MAT (eMAT),[14] and the thermophilic Methanocaldococ
cus jannaschii MAT (mMAT). [15] The basis for inclusion
of the human homologs derives from an interest to interro
gate the substrate specificities of disease-relevant hMATs,
[16] while the additional bacterial and archaeal homologs
were selected to compare and contrast the current study with
prior work relating to their substrate specificities.[9a, 17]

55

60

65

Standard uniform assay conditions (2 mM Met analog, 1
mM ATP, 5 µM MAT, 25 mM Tris, 5 mM MgCl2, 50 mM
KC!, pH 8, 4 h) were adopted to facilitate this broad
assessment. For the thermophilic counterpart (mMAT), reac
tions were conducted at 65° C., while all other reactions
were incubated at 37 ° C. Production of SAM analogs was
determined by an RP-HPLC end point assay to afford
complete analysis of the desired SAM analog and/or any
corresponding degradation products known to directly
derive from the desired SAM analog intermediate. Putative
SAM analog and SAM-derived degradative product formation was subsequently confirmed via high-resolution mass
spectrometry (HRMS) analysis for all positive reactions (see
Table 2).
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TABLE 2
Surnm

of MAT reactions

Percentage Turn-over
Analog

eMAT

2
2-Se
3
3-Se
4
4-Se
6
6-Se
7
7-Se
8
8-Se
9
9-Se
10
10-Se
11
12
12-Se
13
13-Se
14
16
17
18
19
19-Se
21
23
23-Se
24-Se

90
100
2
0
2
2
2
2
2
0
0
0
2
2
0
0
0
0
4
0
0
0
0

H. R. Mass (m/z)

hMATlA hMAT2A hMAT2 mMAT Theoretical
95
100
75
57
2
7
2
4
10
2
0
2
0
0
0
2
4
0
0
0
2
4
7

100
100
90
53
44
13
23
50
42
54
24
2
11
12
22
2
11
12
26
0
4
18
0
4
9
19
9
16

26

100
100
88
82
20
58
20
33
52
59
55
74
2
10
40
55
25
2
12
13
49
0
44
49
0
15
46
12
15
25

100
100
94
73
14
0
16
15
21
27
10
16
17
30
14
12
32
29
13
16
31
32
18
30

Observed

399.1445, 297.0896[a]399_1444, 298.0965[b]
447.0890, 345_034o[a]447_0895, 346.0416[b]
413.1602, 311.1052[a]413.1599, 312.1121[b]
461.1046, 359.0497[a]416.1040, 360.0565[b]
321.0896[a]
322.1051[b]
369.0340[a]
370.0411[b]
322.0848[a]
323.0919[b]
370.0293[a]
371.0371[b]
425.1602, 323.1052[aJ425.1609, 324.1129[b]
371.0497[a]
372.0568[b]
427.1758, 325.1209[a]427.1759, 326.1281[b]
475.1203, 373.0653[a]475_1200, 374.0726[b]
427.1758, 325.1209[a]427_l762, 326.1282[b]
373.0653[a]
374_0743[b]
437.1602, 335.1052[a]437_1599, 336.1124[b]
383.0497[a]
384.0566[b]
439.1758, 337.1209[a]439_l 754, 338.1275[b]
439.1758, 337.1209[a]439_l754, 338.1282[b]
385.0653[a]
386.0730[b]
441.1915, 339.1365[a]441.1966, 340.1477[b]
489.1359, 387.081Q[a]489.1358, 388.0882[b]
441.1915, 339.1365[aJ441.1918, 340.1439[b]
451.1758
451.1756
454.1616, 352.1066[a]454_1615, 353.1140[b]
455.2071, 353.1522[a]455.2123, 354.1634[b]
453.1915
453.2044
399.0810[aJ
400.0878[b]
468.1772, 366.1223[a]468.1772, 367.1296[b]
480.1772, 378.1223[a]480.1768, 379.1292[b]
426.0667[a]
427.0687[b]
400.0762[a]
401.0830[b]

[altheoretical mass of degraded 5'-alkyl-thio(seleno)-5'-deoxyadenosine (MTA); observed mass of degraded 5'-alkyl-thio(seleno)5'-deoxyadenosine (MTA):

[bl[M+H]

A cumulative comparison of the substrate specificity for
all five MAT model systems based upon RP-HPLC is
illustrated in FIG. 5 and FIG. 6 wherein observed 5'-methyl
thio(seleno)-5'-deoxyadenosine (MTA) production (via RP
HPLC) was interpreted as product based upon the well
established SAM decay pathways indicating MTA to
directly derive from SAM (not ATP). [6d, lla, 18] This
cumulative analysis revealed hMAT2 to be the most per
missive of the MATs tested at 37° C., while the thermophilic
mMAT also displayed notable permissivity at 6 5 ° C. Of the
4 7 putative substrates tested with hMAT2, 10 led to appre
ciable (> 50%) SAM analog production, an additional 8 led
to moderate (25-50%) conversion, while 11 offered detect
able product (<25%) under the conditions described. In
general, smaller alkyl substitutions were better tolerated,
suggesting steric infringement to possibly prohibit larger
substitutions. Interestingly, in the case where direct com
parisons could be made, the degree of unsaturation correlated
with
a
reduction
in
turnover
(e.g.,
propyl>allyl>propargyl). Also, in most cases, Se-analogs
were preferred over their S-comparators, most notably for
hMAT2. Consistent with previous studies, [19] the regula
tory beta subunit of MAT2A improved the overall profi
ciency of hMAT2 and, in some cases, this increase in
proficiency translated to a slight increase in permissivity in
the current study. Finally, the addition of inorganic pyro
phosphatase in an attempt to drive the reaction via degra
dation of the pyrophosphate co-product did not appreciably
increase turnover.
Based on these results, the corresponding MATs can be
generally classified as having broad (hMAT2/hMAT2A),
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medium (mMAT) or stringent (eMAT and hMATlA) sub
strate specificities. Superimposition of available X-ray struc
tures (hMATlA, hMAT2A and eMAT) reveal a root mean
square deviation (rmsd) of 0.268 A between hMAT2A and
hMATlA (sequence identity of -85%) and -0.56 A between
eMAT and hMATlA or hMAT2A (sequence identity of
-58%). Structural comparison of the permissive (hMAT2A)
and stringent (hMATlA and eMAT) MATs highlights key
distinctions among residues (FIG. 7). Interestingly, while
hMAT2A active site mutagenesis has led to a slight improve
ment in turnover with an unnatural analog, [6e] the current
structural comparison suggests the broad substrate specific
ity of hMAT2A to be predominately mediated by residues
within the secondary shell and/or on the solvent-exposed
surface distal to active-site loops that likely contribute to
interdomain movement/dynamics. Whether or not these resi
dues contribute to the hMAT2 alpha/beta interface is currently unknown.
To subsequently assess the feasibility of 'alkylrandomization' via a single vessel coupled MAT/MT reaction, the
rebeccamycin MT RebM was selected as the representative
methyl transferase (MT). RebM is the sugar C4'-0-MT
involved in rebeccamycin biosynthesis and has previously
been demonstrated to tolerate both alternative acceptors and
alkyl donors. [5a, 10] The coupled system also employed
standard assay conditions (2 mM Met analog, 1 mM ATP, 50
µM rebeccamycin congener compound31, 5 µM hMAT2, 10
µM RebM, 5 µM SAH-hydrolase, 25 mM Tris, 5 mM
MgCl2 , 50 mM KC!, pH 8, 24 h at 37 ° C.) and included only
S/Se-Met analogs that afforded ;;,;20% turnover with hMAT2
under standard conditions (FIG. 5, FIG. 6). From this pilot
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study, 8 out of 18 of the selected S/Se-Met series led to the
production of the corresponding differentially alkylated
indolocarbazoles in appreciable yields (;;,;40%, FIG. 8 and
FIG. 15). Importantly, inclusion of SAH-hydrolase (SAHH)
in the coupled reaction, to prevent product inhibition associated with most if not all MTs, [20] improved overall
product yields by 15-40%. Notably, this is the first report of
MT-catalyzed acetonitrilylation (See FIG. 8, compound 35
deriving from L-Met analog 6 or 6-Se).
In conclusion, the broad substrate specificity analysis
presented revealed hMAT2/2A and mMAT to display nota
bly broad substrate tolerance. Of these, hMAT2A is over
expressed in a number of tumor types, [21] where inhibition
of hMAT2A by small molecule inhibitors or siRNA affords
dramatic tumor reduction. [22] The discovered substrate
malleability of hMAT2A in conjunction with aberrant can
cer-specific hMAT2A overexpression therefore may offer
the potential to employ suitable S/Se-Met analogs as cell
based metabolic probes of the role of methylation in cancer.
In addition, the work highlighted herein enables one of the
first the facile syntheses of SAM analogs directly compatible
with downstream SAM utilizing enzymes including MTs
and is advantageous over other recently reported chemoen
zymatic strategies that depend upon synthetic non-native
alkylated amino acid alkyl donors and nucleoside acceptors.
As such, this platform circumvents a major liability of
prior SAM analog/MT strategies, namely SAM analog
decomposition, and thereby opens the door to the further
interrogation of a host of MTs which operate upon macro
molecular (protein/nucleic acid) and small molecule (natural
products) substrates. Finally, the strategy presented unveils
a single vessel proof of concept for natural product 'alkyl
randomization' which, while currently somewhat limited via
enzyme specificity, is expected to be further advanced via
MT/MAT directed evolution and/or structure-based engineering in a manner reminiscent to that used for advancing
glycorandomization. [3, 23]
Materials and Methods
Unless otherwise stated, all general chemicals and
reagents were purchased from Sigma-Aldrich (St. Louis,
Mo., USA) or Acros (New Jersey, USA) and were reagent
grade or better. L-homocystine was purchased from Bachem
(Torrance, Calif., USA). L-homocystine [24] and L-seleno
homocysteine [25] were synthesized following previously
published protocols. E. coli BL21(DE3) competent cells
were purchased from Invitrogen (Carlsbad, Calif.). The
pET28a E. coli expression vector was purchased from
Novagen (Madison, Wis.). Primers were purchased from
Integrated DNA Technology (Coralville, Iowa). Pfu DNA
polymerase was purchased from Stratagene (La Jolla,
Calif.). Restriction enzymes and T4 DNA ligase were pur
chased from New England Biolabs (Ipswich, Mass.). PD-10
colunm and Ni-NTA superflow columns were purchased
from GE Healthcare (Piscataway, N.J.).
High-resolution mass spectrometric data were obtained
using a Waters (Milford, Mass.) LCT time-of-flight spec
trometer for electrospray ionization (ESI) or AB SCIEX
TripleTOF® 5600 System. NMR spectra were obtained on
Varian Unity Inova 400 or 500 MHz instruments (Palo Alto,
Calif.) at the NMR facility of College of Pharmacy at
University of Kentucky using 99.8% CDC13 with 0.05% v/v
TMS, 99.8% CD30D or 99.8% D20 from Cambridge Iso
topes (Cambridge Isotope Laboratories, MA, USA). 1H and
13
C chemical shifts were referenced to internal solvent
resonances. Multiplicities are indicated by s (singlet), d
(doublet), t (triplet), q (quartet), quin (quintet), m (multi
plet), and br (broad). Chemical shifts are reported in parts
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per million (ppm) and coupling constants J are given in Hz.
Routine 13C NMR spectra were fully decoupled by broad
broad WALTZ decoupling. All NMR spectra were recorded
at ambient temperature.
Normal-phase flash chromatography was performed on
40-63 µm, 60 A silica gel (from Silicycle, Quebec, Canada).
Analytical TLC was performed on silica gel glass TLC
plates (from EMD chemical Inc). Visualization was accom
plished with UV light (254 nm) followed by staining with
dilute sulfuric acid (5% in ethanol) solution or 10% ninhy
drin in ethanol and heating. High performance liquid chro
matography (HPLC) was accomplished using an Agilent
1260 system equipped with a diode array detector (DAD).
Method A (HPLC):
Analytical reverse-phase (RP) HPLC was conducted with
a Luna C-18 (5 µm, 4.6 mmx250 mm) column (Phenom
enex, Torrance, Calif., USA) [gradient of 1% B to 40% B
over 22 min, 55% B to 100% B over 3 min, 100% B for 6
min, 100% B to 5% B over 1 min, 5% B for 3 min
(A=ddH20 with 0.1% TFA; B=acetonitrile) flow rate=l mL
min- 1 ; A218]. The reaction was monitored by the retention
time difference between starting material and product.
Method B (HPLC):
Semi-preparative RP HPLC was conducted on a Gemini
C18 (5 µm, 10x250 mm; Phenomenex, Torrance, Calif.,
USA) colunm to purify the methionine analogs [gradient of
5% B to 55% B over 25 min, 55% B to 100% B over 2 min,
100% B for 6 min, 100% B to 5% B over 1 min, 5% B for
4 min (A=ddH20 with 0.1% TFA; B=acetonitrile) flow
rate=4.5 mL mind; A218].
Method C (Flash Chromatography):
Pilot reversed-phase purification was conducted by flash
column chromatography using an Alltech C18 Extract-Clean
column (10,000 mg, 75 mL, Alltech Associates, Deerfield,
Ill., USA) for the scale-up purification of methionine ana
logs. The column was pre-equilibrated with ddH20/0.1%
TFA and after loading the solid crude material, a gradient of
100/0 to 60/40 water:acetonitrile containing 0.1% TFA was
used as the mobile phase. Eluted fractions were checked by
TLC (15:1:84 MeOH/NH40H/CHCl3, ninhydrin stain) and
confirmed via analytical HPLC (Method A) to identify
product fractions.
Method D (HPLC):
To monitor MAT reactions, analytical RP HPLC
employed a Luna C18 colunm (5 µm, 4.6 mmx250 mm;
Phenomenex, Torrance, Calif., USA) [gradient of 10% B to
40% B over 15 min, 40% B to 75% B over 5 min (A=lO mM
NaH2P04, 5 mM octane sulfonic acid, pH was adjusted to
3.5 using phosphoric acid; B=acetonitrile) flow rate=l mL
min-1; A254].
Method E (HPLC):
To monitor the coupled hMAT2/RebM reactions, analyti
cal RP HPLC was conducted with a Luna C18 colunm (5 µm,
4.6 mmx250 mm; Phenomenex, Torrance, Calif., USA)
[gradient of 10% B to 100% B over 20 min (A=ddH20 with
0.1% TFA; B=acetonitrile) flow rate=l mL min- 1 ; A31 5].
The sequence of MATs involved in this study can be
found within the National Center for Biotechnology Infor
mation (NCBI) Protein database and include: Homo sapiens
MAT2A (hMAT2A; genebank accession number
AAH01686.1); Homo sapiens MATlA (hMATlA, genebank
accession number AAQ89058.1); Homo sapiens MAT II
(co-expression of MAT2A with MAT2B; genebank acces
sion number AAH01686.1); Escherichia coli MAT (eMAT;
genebank accession number AAG58073.1); and Methano
caldococcus jannaschii (mMAT; genebank accession num
ber Q58605.1).
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All DNA sequencing was conducted by the University of
Wisconsin Biotechnology Center with the primers T7 pro
moter. All Luria-Bertani (LB) media and agar were supple
mented with 35 µg mL-1 kanamycin. High-throughput assay
absorbance readings were conducted using a FLUOstar
Omega plate reader (BMG Labtechnologies, Cary, N.C.,
USA). HPLC peak areas were integrated with Star Chro
matography Workstation Software (Varian, Palo Alto, Calif.,
USA) and the percent conversion calculated as a percent of
the total peak area. High resolution electrospray ionization
(ESI) mass spectra were recorded on a AB Sciex Triple TOF
5600 instrument coupled with an Eksigent Ekspert micro LC
200 system with source temperature of 150° C., ion spray
voltage floating (ISVF) of 5000 V in positive mode. Samples
were infused at 20 µL min-1 and spectra collected for 3 min
at a resolution greater than 31000. In negative mode ISVF
of -4000 V was used. Cl 7 lysophosphatidyl choline with a
mass of 510.3554 and Cl 7 lysophosphatidic acid with a
mass of 423.2517 were used as internal references to cali
brate the spectra in positive and negative modes respec
tively.
General Procedure of for Azido Installation
(FIG. 9, used for compounds 17, 21, 23, 23-Se, 28, 29 and
30). Dibromo-alkane (1.0 g, 1.0 eq) was dissolved in 20 mL
CH2 Cl2 and to this was added nBu4NHS04 (0.5 eq) and
NaN3 (0.8 eq) under stirring. A 20 mL sat. NaHC03 solution
was subsequently added and the reaction was stirred vigor
ously for 2 h. The organic layer was washed with water and
brine (20 mL each) and then dried over Na2 S04. After the
CH2 Cl2 solvent was concentrated in vacuo carefully, the
product was used directly as a monobromo or dibromo
mixture without further purification for the alkylation reac
tion.
General Procedure for the Na/NH3 Reduction & S-Alky
lation of L-Homocystine
(FIG. 10, used for compounds 3, 4, 5, 8-19, 21-23, 25, 26
and 28-30). L,L-homocystine (100 mg, 0.37 mmol) (from
Bachem, Torrance, Calif., USA) was added to 20 mL liquid
ammonia at -78° C. and stirred until fully dissolved. Small
fragments of sodium metal (34 mg, 1.5 mmol) were added
until a deep blue color persisted for at least 1 min. The
corresponding alkyl bromide (2.0 eq) was then introduced,
which caused the blue solution to quickly proceed to a
mixture with a white precipitate. Ammonium chloride (20
mg, 0.37 mmol) was then added to the reaction and the
reaction was immediately removed from the cooling bath.
The reaction flask was left open to the atmosphere at
ambient temperature to allow ammonia to evaporate. The
resulting residue was dissolved in 5 mL deionized water and
the pH was adjusted to pH 5-7 by the addition of 1 M HCI.
The solvent was removed under reduced pressure and the
residue was dried. A fraction (10 mg) of the dried residue
was dissolved with 400 µL dH2 0 with 0.1% TFA, adjusted
to pH 3 by the addition of 1 M HCI, centrifuged and
subsequently purified by semi-preparative HPLC (Method
B) to ultimately afford the desired S-alkylated L-methionine
analogs in 22%-99% yield.
General Procedure for the S-Alkylation of L-Homocyste
me
(FIG. 11, used for compounds 6, 7, 20 and 27). L-homo
cysteine [SIJ (10 mg, 0.07 mmol) was dissolved in 1 mL
acetone and to this was added the corresponding alkyl
bromide (2.0 eq) and K2 C03 (20 mg, 0.14 mmol). The
reaction was stirred under room temperature until HPLC
indicated the completion of the reaction (Method A). The
solvent was removed in vacuo, the resulting residue was
dissolved in 400 µL dH2 0 with 0.1% TFA, adjusted to pH
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3 by the addition of 1 M HCI, centrifuged and subsequently
purified by semi-preparative HPLC (Method B) to ulti
mately afford the desired S-alkylated L-methionine analogs
in 20%-60% yield.
General Procedure for the Na/NH3 Reduction & Alky
lation of L-Selenohomocystine
(FIG. 11, used for compounds 3-Se, 4-Se, 7-Se, 12-Se and
23-Se). L-Selenohomocystine [s2J (100 mg, 0.27 mmol) was
treated in manner identical to that described in the section
labeled "general procedure for the Na/NH3 reduction &
S-alkylation of L-homocysteine" to provide the desired Sealkylated L-selenomethionine analogs in yields ranging from
16%-85% yield.
General procedure for NaBH4 reduction & Se-alkylation
of L-selenohomocystine
(FIG. 13, used for compounds 6-Se, 8-Se, 10-Se, 13-Se,
15-Se, 19-Se, 20-Se, 24-Se, 27-Se). According to a proce
dure from Zhang et al., [26] to the THF solution of L-sele
nohomocystine [s2J (100 mg, 0.276 mmol) in a small flask
was added alkyl bromide (4.0 eq) under N2 with stirring at
room temperature. NaBH4 (83.5 mg, 2.21 mmol, 8 eq) was
dissolved in 0.12 M NaOH/water, and this solution was
introduced to the reaction flask drop-wise via syringe. The
reaction was subsequently stirred under N2 at room temperature for 5 h and then adjusted to pH 5-7 by addition of
1 M HCI. The solvent was removed completely under
reduced pressure and the residue was dried. A portion (10
mg) of the dried residue was dissolved with 400 µL H20
with 0.1% TFA, adjusted to pH 3 by addition of 1 M HCI,
centrifuged and the supernatant was purified by preparative
HPLC (Method B) to provide the desired Se-alkylated
L-selenomethionine analogs in yields ranging from 18%99% yield.
General Procedure for the Demethylation & Se-Alkylation of L-Selenomethionine
(FIG. 14, used for compounds 9-Se, 22-Se). According to
a procedure from Dekker, et al, [27] L-selenomethionine
(100 mg, 0.51 mmol) was dissolved in 5 mL of concentrated
HCI and to this was added the corresponding alkyl bromide
(5.0 eq). The reaction was refluxed at 100° C. for 12 h. The
reaction was then allowed to cool down to room tempera
ture, diluted with water (10 mL), and adjusted with 30%
NH40H to pH=7. The solvent was concentrated under
reduced pressure to less than 1 mL, frozen at -80° C., and
lyophilized to form a dry powder. The powder was purified
by reversed-phase flash chromatography (Method C), to
give 9-Se (9% yield) and 22-Se (7% yield).
Example
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(2S)-2-amino-4-(ethylsulfanyl)butanoic acid
(compound 3)
Some modifications of the strategy illustrated in FIG. 10
were employed for the synthesis of compound 3. Specifi
cally, the dried residue after completion of the L-homocys
tine (250 mg, 0.932 mmol)/iodoethane (165 µL, 2.04 mmol)
and subsequent evaporation of NH3 was dissolved in ddH20
(30 mL) and solid NaOH (1.20 g, 0.03 mo!) was added,
creating a 1 M sodium hydroxide solution. After stirring for
1 h, the basic solution was slowly loaded onto a Dowex
50W8X-200 2.5 cmx3 cm colunm prequilibrated with
ddH2 0. The colunm was washed with several colunm vol
umes of ddH2 0 and the product subsequently eluted with
2.5% aqueous NH40H. The fractions, identified by TLC
(15:1:84 MeOH/NH40H/CHCl3, ninhydrin stain), were
combined and lyophilized to a white amorphous solid (184
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mg, 61% yield). 1 H NMR (DMSO-d6/TFA-d1 =20/1, 500
MHz) Ii 4.01 (t, 1=6.2 Hz, lH), 2.48-2.64 (m, 2H), 2.49 (q,
1=7.3 Hz, 2H), 2.00 (m, 2H), 1.17 (t, 1=7.3 Hz, 3H); 13C
NMR (DMSO-diTFA-d1=20/1, 125 MHz) Ii 175.9, 56.3,
35.4, 31.4, 30.0, 20.1; HRESI calculated for C6H14N02S
([M+Hr) m/z 164.0740; measured m/z 164.0744.

(m, 2H); 13C NMR (D2 0, 125 MHz) Ii 171.4, 118.5, 51.4,
29.0, 27.3, 16.1; HRESI calculated for C6H11N2 02S ([M+
Hr) m/z 175.0536; measured m/z 175.0534.
5

FIG. 12 with bromoethane yielded compound 3-Se (4.1
mg, 85% yield) as a white solid. 1H NMR (D2 0, 400 MHz)
Ii 3.85 (t, 1=6.2 Hz, lH), 2.43-2.50 (m, 4H), 2.01-2.11 (m,
2H), 1.19 (t, 1=7.6 Hz, 3H); 1 3C NMR (D2 0, 100 MHz) Ii
172.6, 53.5, 30.8, 17.0, 16.8, 14.7; HRESI calculated for
C6H14N02Se ([M+Hr) m/z 212.0184; measured m/z
212.0187.
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FIG. 10 with propargyl bromide yielded compound 4 (4.5
mg, 75% yield) as a white solid together with compound 5
(0.3 mg) as a white oil. 1H NMR (D2 0/TFA=20/1, 400
MHz) ll 4.09 (t, 1=6.4 Hz, lH), 3.24 (d, 1=2.8 Hz, 2H), 2.74
(t, 1=6.8 Hz, 2H), 2.53 (t, 1=2.4 Hz, lH), 2.07-2.26 (m, 2H);
13
C NMR (D2 0/TFA=20/1, 100 MHz) Ii 171.3, 80.0, 72.0,
51.4, 28.8, 26.0, 17.8; HRESI calculated for C7H12N02S
([M+Hr) m/z 174.0583; measured m/z 174.0582.
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FIG. 10 with propargyl bromide yielded compound 5 (0.3
mg, 6% yield) as a white oil together with compound 4 (4.5
mg, 75% yield) as a white solid. 5.69 (t, 1=6.4 Hz, lH), 4.94
(d, 1=10.4 Hz, 2H), 4.06 (t, 1=6.4 Hz, lH), 2.70 (t, 1=7.6 Hz,
2H), 2.07-2.19 (m, 2H); HRESI calculated for C7H12N02S
([M+Hr) m/z 174.0583; measured m/z 174.0582.
Example

(2S)-2-amino-4-(prop-2-en-1-ylselanyl)butanoic
acid ( compound 7-Se)

40
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Example
(2S)-2-amino-4-(propylsulfanyl)butanoic acid
(compound 8)

50

55
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(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic
acid ( compound 6)
FIG. 11 with L-homocysteine (10 mg, 74 µmo!) and
bromoacetonitrile yielded compound 6 (7.6 mg, 59% yield)
as a white solid. 1 H NMR (D2 0, 500 MHz) Ii 4.10 (t,

FIG. 11 with ally! bromide yielded compound 7 (5.3 mg,
41% yield) as a white solid. 1H NMR (D2 0/TFA=20/1, 400
MHz) ll 5.61-5.72 (m, lH), 5.04 (d, 1=10.8 Hz, lH), 4.98 (d,
1=2.0 Hz, lH), 3.85 (t, 1=6.8 Hz, lH), 3.05 (dd, 1=7.2, 0.8
Hz, 2H), 2.48 (t, 1=7.6 Hz, 2H), 1.92-2.10 (m, 2H); 1 3C
NMR (DMSO-d6/TFA-d1 =8/1, 125 MHz) Ii 171.2, 134.9,
117.9, 51.5, 34.0, 30.4, 25.9; HRESI calculated for
C7H14N02S ([M+Hr) m/z 176.0740; measured m/z
176.0728.

FIG. 12 with ally! bromide yielded compound 7-Se (3.0
mg, 59% yield) as a white solid. 1H NMR (D2 0, 400 MHz)
Ii 5.70-5.77 (m, lH), 4.9 (m, 2H), 3.90 (t, 1=6.3 Hz, lH),
3.08 (d, 1=7.8 Hz, 2H), 2.45 (t, 1=8.2 Hz, 2H), 2.03-2.10 (m,
2H); 13 C NMR (D2 0, 100 MHz) ll 172.1, 134.6, 116.6, 53.2,
30.5, 25.2, 16.7; HRESI calculated for C7H14N02Se ([M+
Hr) m/z 224.0184; measured m/z 224.0179.

Example
(2S)-2-amino-4-(propa-l,2-dien-1-ylsulfanyl)bu
tanoic acid ( compound 5)

(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic
acid ( compound 7)

Example

(2S)-2-amino-4-(prop-2-yn-1-ylselanyl)butanoic
acid (compound 4-Se)
FIG. 12 with propargyl bromide yielded compound 4-Se
(0.8 mg, 16% yield) as a white solid. 1H NMR (D2 0, 400
MHz) Ii 3.97 (t, 1=6.3 Hz, lH), 3.15 (t, l= l.6 Hz, 2H), 2.74
(t, 1=7.6 Hz, 2H), 2.49 (t, 1=2.6 Hz, lH), 2.08-2.27 (m, 2H);
13
C NMR (D2 0, 100 MHz) ll 172.0, 81.3, 72.0, 53.0, 30.3,
18.4, 6.3; HRESI calculated for C7H12N02Se ([M+Hr) m/z
222.0028; measured m/z 222.0035.

FIG. 13 with bromoacetonitrile yielded compound 6-Se
(1.2 mg, 20% yield) as a white solid. 1H NMR (D2 0, 400
MHz) Ii 3.91 (t, 1=6.5 Hz, lH), 3.29 (s, 2H), 2.81 (dd,
1=15.6, 6.8 Hz, lH), 2.77 (dd, 1= 13.2, 6.8 Hz, lH), 2.11-2.29
(m, 2H); 1 3C NMR (D2 0, 100 MHz) Ii 172.3, 119.6, 53.2,
30.4, 19.9, 1.9; HRESI calculated for C6H11N2 02Se ([M+
Hr) 222.9980; measured m/z 222.9973.
Example

Example
(2S)-2-amino-4-(prop-2-yn-1-ylsulfanyl)butanoic
acid (compound 4)

Example
(2S)-2-amino-4-[(cyanomethyl)selanyl]butanoic acid
(compound 6-Se)

Example
(2S)-2-amino-4-( ethylselanyl)butanoic acid ( com
pound 3-Se)
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1=6.5H, lH), 3.46 (s, 2H), 2.80 (t, 1=11.5 Hz, 2H), 1.98-2.27

A protocol identical to that described for compound 3
using L-homocystine (150 mg, 0.559 mmol) and 1-bro
mopropane (112 µL, 1.23 mmol) gave compound 8 (181 mg,
91% yield) as a white amorphous solid. 1 H NMR (DMSO
diTFA-d1=20/1, 400 MHz) Ii 4.05 (t, 1=6.8 Hz, lH), 2.61
(m, 2H), 2.50 (t, 1=7.3 Hz, 2H), 2.03-2.09 (m, 2H), 1.56
(quin, 1=7.3 Hz, 2H), 0.96 (t, 1=7.2 Hz, 3H); 1 3C NMR
(DMSO-diTFA-d1=20/1, 125 MHz) Ii 171.2, 51.5, 33.3,
30.6, 26.9, 22.9, 13.6; HRESI calculated for C7H16N02S
([M+Hr) m/z 178.0896; measured m/z 178.0900.
Example
(2S)-2-amino-4-(propylselanyl)butanoic acid ( com
pound 8-Se)

65

FIG. 13 with 1-bromopropane yielded compound 8-Se
(3.1 mg, 50% yield) as a white solid. 1H NMR (D2 0, 400

US 9,879,043 Bl
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MHz) Ii 3.97 (t, 1=6.8 Hz, lH), 2.34 (t, 1=7.6 Hz, 2H), 2.27
(t, 1=7.0 Hz, 2H), 1.95-2.13 (m, 2H), 1.30 (dt, 1=7.2, 7.0 Hz,
2H), 0.59 (t, 1=7.2 Hz, 3H); 1 3C NMR (D20, 100 MHz) Ii
171.3, 52.6, 30.4, 25.9, 22.9, 17.1, 13.5; HRESI calculated
for C7H 16 N02Se ([M+Hi +) m/z 226.0341; measured m/z
226.0353.

34

Example
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Example
(2S)-2-amino-4-(propan-2-ylsulfanyl)butanoic acid
(compound 9)
FIG. 10 with 2-bromopropane yielded compound 9 (1.2
mg, 22% yield) as a white solid. 1H NMR (D20, 400 MHz)
Ii 4.01 (t, 1=6.5 Hz, lH), 2.89 (quin, 1=6.8 Hz, lH), 2.59 (t,
1=7.4 Hz, 2H), 1.96-2.12 (m, 2H), 1.09 (d, 1=6.7 Hz, 6H);
13
C NMR (D20, 100 MHz) ll 171.8, 52.0, 34.2, 29.8, 24.8,
22.2 (2 carbons); HRESI calculated for C7H 16 N02S ([M+
Hr) m/z 178.0896; measured m/z 178.0887.

10

15

FIG. 14 with 2-bromopropane (0.24 mL, 2.54 mmol)
yielded compound 9-Se (10 mg, 9% yield) as a white solid.
L-selenomethionine (94.9 mg) was recovered after flash
reversed-phase chromatography via Method C. 1H NMR
(D20, 400 MHz) ll 3.83 (t, 1=6.3 Hz, lH), 3.09 (quin, 1=6.85
Hz, lH), 2.55 (t, 1=7.8 Hz, 2H), 2.04-2.17 (m, 2H), 1.24 (d,
1=7.0 Hz, 6H); 1 3C NMR (D20, 100 MHz) Ii 110.0, 53.9,
31.3, 29.4, 23.5, 23.4, 16.7; HRESI calculated for
C7H 16 N02Se ([M+Hr) m/z 226.0341; measured m/z
226.0333.
Example
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(2S)-2-amino-4-(but-3-yn-1-ylsulfanyl)butanoic acid
(compound 10)
FIG. 10 with 4-bromo-1-butyne yielded compound 10
(1.9 mg, 33% yield) as a white oil. 1H NMR (D20, 400
MHz) Ii 3.88 (t, 1=6.4 Hz, lH), 2.62 (t, 1=5.2 Hz, 2H), 2.58
(t, 1=7.2 Hz, 2H), 2.40 (td, 1=6.8 Hz, 2.4 Hz, lH), 2.27 (t,
1=2.54 Hz, lH), 1.98-2.14 (m, 2H); 13 C NMR (D20, 100
MHz) Ii 172.8, 83.6, 70.3, 52.7, 29.8, 29.5, 26.4, 18.6;
HRESI calculated for C8H 14N02S ([M+Hr) m/z 188.0740;
measured m/z 188.0759.
Example

45

(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)sulfanyl]
butanoic acid (compound 12)
A protocol identical to that described for compound 3
using L-Homocystine (150 mg, 0.559 mmol) and 3-bromo2-methylpropene (223 µL, 2.20 mmol) gave Compound 12
(169 mg, 80% yield) was obtained as a white amorphous
solid. 1 H NMR (DMSO-diTFA-d 1=20/1, 400 MHz) ll 4.88
(dd, 1=4.6, 3.2 Hz, 2H), 4.04 (t, 1=6.4 Hz, lH), 3.15 (s, 2H),
2.53 (m, 2H), 2.05-2.09 (m, 2H), 1.78 (s, 3H); 13 C NMR
(DMSO-diTFA-d 1=20/1, 125 MHz) ll 171.1, 141.4, 136.5,
51.5, 38.4, 30.1, 26.1, 20.8; HRESI calculated for
C8H 16 N02S ([M+Hr) m/z 190.0896; measured m/z
190.0904.
Example
(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)selanyl]
butanoic acid (compound 12-Se)
FIG. 12 with 3-bromo-2-methylpropene yielded compound 12-Se (5.0 mg, 85% yield) as a white solid. 1H NMR
(D20, 400 MHz) Ii 4.6 (m, 2H), 3.99 (t, 1=6.5 Hz, lH), 3.11
(s, 2H), 2.43-2.50 (m, 2H), 1.98-2.11 (m, 2H), 1.54 (s, 3H);
13
C NMR (D20, 100 MHz) ll 171.4, 142.4, 113.0, 52.7, 30.5,
30.3, 20.0, 17.2; HRESI calculated for C8H 1 5 N0 2SeNa
([M+Nar) m/z 260.0160; measured m/z 260.0157.
Example
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(2S)-2-amino-4-(but-3-yn-1-ylselanyl)butanoic acid
(compound 10-Se)
FIG. 13 with 4-bromo-1-butyne yielded compound 10-Se
(2.1 mg, 33% yield) as a light yellow solid. 1 H NMR (D20,
400 MHz) Ii 3.92 (t, 1=6.3 Hz, lH), 2.61 (t, 1=6.8 Hz, 2H),
2.57 (t, 1=8.0 Hz, 2H), 2.44 (td, 1=7.2 Hz, 2.8 Hz, 2H), 2.20
(t, 1=2.4 Hz, lH), 2.02-2.20 (m, 2H); 1 3C NMR (D20, 100
MHz) Ii 172.1, 84.3, 70.1, 53.1, 30.7, 21.4, 19.5, 17.7;
HRESI calculated for C8H 14N02Se ([M+Hr) m/z
236.0184; measured m/z 236.0200.

A protocol identical to that described for compound 3
using L-homocystine (150 mg, 0.559 mmol) and (2E)-1bromo-2-butene (125 µL, 1.23 mmol) gave compound 11
(169 mg, 80% yield) as a white amorphous solid. 1 H NMR
(D20, 400 MHz) ll 5.40 (m, lH), 5.24 (m, lH), 3.97 (t, 1=6.0
Hz, lH), 2.92 (d, 1=7.2 Hz, 2H), 2.42 (t, 1=7.6 Hz, 2H),
1.91-2.03 (m, 2H), 1.44 (d, 1=5.6 Hz, 3H); 1 3C NMR (D20,
100 MHz) Ii 171.4, 129.8, 125.9, 51.7, 32.4, 29.11, 24.6,
16.7. HRESI calculated for C8H 16 N02S ([M+Hr) m/z
190.0896; measured m/z 190.0904.
Example

Example
(2S)-2-amino-4-(propan-2-ylselanyl)butanoic acid
(compound 9-Se)

(2S)-2-amino-4-[(2E)-but-2-en-1-ylsulfanyl]butanoic
acid (compound 11)
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(2S)-2-amino-4-(butylsulfanyl)butanoic acid
(compound 13)
FIG. 10 with 1-bromobutane yielded compound 13 (6.4
mg, 99% yield) as a white solid. 1H NMR (D20, 400 MHz)
ll 4.00 (t, 1=6.3 Hz, lH), 2.56 (t, 1=7.4 Hz, 2H), 2.45 (t, 1=7.2
Hz, 2H), 1.96-2.11 (m, 2H), 1.41 (quin, 1=7.4 Hz, 2H), 1.23
(dt, 1=7.4, 6.8 Hz, 2H), 0.73 (t, 1=7.2 Hz, 3H); 1 3C NMR
(D20, 100 MHz) ll 172.0, 52.1, 30.6, 30.4, 29.5, 26.2, 21.2,
12.7; HRESI calculated for C8H 18N02S ([M+Hr) m/z
192.1053; measured m/z 192.1074.
Example
(2S)-2-amino-4-(butylselany1)butanoic acid (com
pound 13-Se)
FIG. 13 with 1-bromobutane yielded compound 13-Se
(9.3 mg, 100% yield) as a white solid. 1H NMR (D20, 400

35
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MHz) ll 4.01 (t, 1=6.5 Hz, lH), 2.53 (m, 4H), 2.05-2.15 (m,
2H), 1.49 (quin, 1=7.4 Hz, 2H), 1.23 (dt, 1=7.6, 7.4 Hz, 2H),
0.74 (t, 1=7.4 Hz, 3H); 13 C NMR (D20, 100 MHz) ll 171.8,
52.8, 31.6, 30.6, 23.4, 22.2, 17.1, 12.6; HRESI calculated for
C8H 18N02Se ([M+Hr) m/z 240.0497; measured m/z
240.0510.

5

Example
(2S)-2-amino-4-[(2-methylpropy1)sulfanyl]butanoic
acid (compound 14)
FIG. 10 with 2-bromo-propane yielded compound 14 (6.4
mg, 99% yield) as a white solid. 1 H NMR (D20/TFA=20/1,
400 MHz) Ii 4.04 (t, 1=6.3 Hz, lH), 2.54 (t, 1=7.4 Hz, 2H),
2.32 (d, 1=7.0 Hz, 2H), 2.00-2.12 (m, 2H), 1.6 (m, lH), 0.78
(d, 1=6.7 Hz, 6H); 13 C NMR (D20/TFA=20/1, 100 MHz) Ii
171.5, 51.6, 39.9, 29.4, 27.7, 26.8, 21.0 (2 carbons); HRESI
calculated for C8H 18N02S ([M+Hr) m/z 192.1053; mea
sured m/z 192.1043.

Example
10

15
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Example
(2S)-2-amino-4-[(3-aminopropyl)sulfanyl]butanoic
acid (compound 15)
FIG. 10 with 3-bromopropylamine hydrobromide yielded
compound 15 (1.4 mg, 24% yield) as a white solid. 1 H NMR
(D20, 400 MHz) ll 3.89 (t, 1=6.3 Hz, lH), 2.96 (t, 1=7.6 Hz,
2H), 2.51-2.58 (m, 4H), 1.99-2.10 (m, 2H), 1.82 (quin, 1=7.3
Hz, 2H); 13 C NMR (D20, 100 MHz) Ii 172.8, 52.6, 38.3,
29.7, 27.3, 26.2 (2 carbons); HRESI calculated for
C7H 17N202S ([M+Hr) m/z 193.1005; measured m/z
193.1019.
Example
(2S)-2-amino-4-[(3-aminopropyl)selanyl]butanoic
acid (compound 15-Se)
FIG. 13 with 3-bromopropylamine hydrobromide yielded
compound 15-Se (5.7 mg, 86% yield) as a white solid. 1H
NMR (D20, 400 MHz) Ii 3.97 (t, 1=6.3 Hz, lH), 2.94 (t,
1=7.4 Hz, 2H), 2.56 (m, 4H), 2.08-2.13 (m, 2H), 1.87 (quin,
1=7.4 Hz, 2H); 13 C NMR (D20, 100 MHz) Ii 172.0, 52.9,
39.1, 30.6, 27.2, 19.1, 17.5. HRESI calculated for
C7H 17N202Se ([M+Ht) m/z 241.0450; measured m/z
241.0465.
Example
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(2S)-2-amino-4-[(2-azidoethyl)sulfanyl]butanoic
acid (compound 17)
FIG. 9 with dibromomoethane (0.46 mL, 5.32 mmol)
yielded a mixture of dibromoethane: l-azido-2-bromoethane
(1:2, 1.0 g). FIG. 10 with this mixture yielded compound 17
(2.1 mg, 33% yield) as a white solid together with dimer
Compound 28 (4.2 mg, 46% yield) as a white solid. Com
pound 17: 1 H NMR (D20, 400 MHz) ll 3.88 (t, 1=6.5 Hz,
lH), 3.39 (t, 1=6.5 Hz, 2H), 2.65 (t, 1=6.5 Hz, 2H), 2.58 (t,
1=7.4 Hz, 2H), 1.96-2.11 (m, 2H); 13 C NMR (D20, 100
MHz) Ii 172.6, 52.5, 50.2, 30.2, 29.8, 26.5; HRESI calcu
lated for C6H 13N402S ([M+Ht) m/z 205.0754; measured
m/z 205.0767.
Example
(2S)-2-amino-4-[(3-methylbutyl)sulfanyl]butanoic
acid (compound 18)
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FIG. 10 with l-bromo-3-methylbutane yielded compound
18 (6.5 mg, 99% yield) as a white solid. 1 H NMR (D20/
TFA=20/1, 400 MHz) ll 4.03 (t, 1=6.5 Hz, lH), 2.52 (t, 1=7.4
Hz, 2H), 2.41 (t, 1=7.8 Hz, 2H), 1.94-2.05 (m, 2H), 1.381.47 (m, lH), 1.23-1.31 (q, 1=7.6 Hz, 2H), 0.68 (d, 1=6.7 Hz,
6H); 13 C NMR (D20/TFA=20/1, 100 MHz) Ii 171.5, 51.6,
37.5, 29.3, 28.7, 26.6, 26.1, 21.3 (2 carbons). HRESI cal
culated for C9H20N02S ([M+Ht) m/z 206.1209; measured
m/z 206.1223.
Example
(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)sulfanyl]
butanoic acid (compound 19)

45

50

(2S)-2-amino-4-[(2E)-penta-2,4-dien-1-ylsulfanyl]
butanoic acid (compound 16)
According to the protocol reported by Sato et al., [28] to
a 50 mL solution of 1,4-pentadien-3-ol (0.5 g, 5.94 mmol)
in water was added 48% HBr in water (1.2 g, 7.13 mmol)
drop wise. The reaction was stirred at 0° C. until TLC
indicated the reaction was complete (-2 h). The reaction was
then diluted with ether and washed with NaHC03 (sat, 3x30
mL), water, and brine. The organic layer was dried with
Na2S04 and concentrated in vacuo to afford 4-bromo-1,3pentadiene (0.46 g, 3.2 mmol) as a yellow liquid with a yield
of 53%. FIG. 10 with this 4-bromo-1,3-pentadiene yielded
compound 16 (1.4 mg, 22%) as a white solid. 1H NMR
(D20, 400 MHz) Ii 6.10 (dt, 1=17.1, 10.2 Hz, lH), 5.92 (dd,
1=15.3, 10.6 Hz, lH), 5.42 (dt, 1=15.1, 7.7 Hz, lH), 4.94 (dd,
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1=16.8, 1.6 Hz, lH), 4.80 (dd, 1=10.8, 1.4 Hz, lH), 3.91 (t,
1=6.5 Hz, lH), 2.95 (d, 1=7.4 Hz, 2H), 2.35 (t, 1=7.2 Hz,
2H), 1.80-1.99 (m, 2H); 13 C NMR (D20, 100 MHz) ll 171.2,
136.1, 133.5, 129.2, 117.2, 51.3, 32.1, 29.0, 24.8. HRESI
calculated for C9H 16N02S ([M+Hr) m/z 202.0896; mea
sured m/z 202.0905.
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A protocol identical to that described for compound 3
using L-Homocystine (150 mg, 0.559 mmol) and 3,3-dim
ethylallyl bromide (250 µL, 2.15 mmol) gave compound 19
(304 mg, 76% yield) as a white amorphous solid. 1 H NMR
(DMSO-diTFA-d 1=20/1, 500 MHz) Ii 5.16 (t, 1=7.8 Hz,
lH), 4.00 (t, 1=6.2 Hz, lH), 3.12 (d, 1=7.7 Hz, 2H),
2.49-2.56 (m, 2H), 1.94-2.04 (m, 2H), 1.68 (s, 3H), 1.61 (s,
3H); 13 C NMR (DMSO-d6/TFA-d 1=20/1, 125 MHz) Ii
175.8, 140.1, 125.7, 56.3, 35.5, 33.8, 31.3, 30.7, 22.9;
HRESI calculated for C9H 18N02S ([M+Hr) m/z 204.1053;
measured m/z 204.1053.
Example
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(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)selanyl]
butanoic acid (compound 19-Se)
FIG. 13 with 3,3-dimethylallyl bromide yielded com
pound 19-Se (2.8 mg, 41% yield) as a white solid. 1H NMR
(D20/TFA=20/1, 400 MHz) Ii 5.19-5.26 (m, lH), 3.92 (t,
1=6.3 Hz, lH), 3.17 (d, 1=8.6 Hz, 2H), 2.49 (t, 1=8.0 Hz,
2H), 2.04-2.18 (m, 2H), 1.59 (s, 3H), 1.52 (s, 3H); 13 C NMR
(D20/TFA=20/1, 100 MHz) Ii 175.8, 140.1, 125.7, 56.4,
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35.5, 33.8, 31.3, 30.7, 22.9. HRESI calculated for
C9H 18 N02Se ([M+Hr) m/z 252.0497; measured m/z
252.0512.

138.0, 128.8 (2 carbons), 128.7 (2 carbons), 127.2, 51.4,
34.6, 29.1, 25.5; HRESI calculated for CuH 1 5 N02SNa
([M+Nar) m/z 248.0716; measured m/z 248.0716.

Example

Example

(2S)-2-amino-4-(cyclohex-2-en-1-ylsulfanyl)bu
tanoic acid (compound 20)

(2S)-2-amino-4-(benzylselanyl)butanoic acid (com
pound 22-Se)

FIG. 11 with L-selenomethionine (100 mg, 0.51 mmol)
FIG. 11 with 3-bromo-cyclohexene yielded compound 20 1°
(4.6 mg, 30% yield) as a white solid. 1H NMR (D20, 400
and benzyl bromide (0.24 mL, 2.03 mmol) yielded com
pound 22-Se (10 mg, 7% yield) as a white solid
MHz) Ii 5.70-5.77 (m, lH), 5.56 (d, 1=8.2 Hz, lH), 4.01 (dt,
and L-selenohomocystine (70 mg, 0.19 mmol, 38% yield).
1=6.4, 0.3 Hz, lH), 3.37 (br. s, lH), 2.54-2.69 (m, 2H),
1
H NMR (D20, 400 MHz) Ii 7.11 (s, 2H), 7.10 (s, 2H),
1.97-2.20 (m, 2H), 1.77-1.89 (m, 3H), 1.39-1.66 (m, 3H);
13
1
5
C NMR (D20, 100 MHz) Ii 171.8, 131.1, 126.7, 51.9,
7.00-7.06 (m, lH), 3.86 (t, 1=6.5 Hz, lH), 3.62 (s, 2H),
39.94, 39.91, 28.54, 28.51, 24.2, 19.0; HRESI calculated for
2.33-2.39 (m, 2H), 1.90-1.97 (m, 2H); 13C NMR (D20, 100
C 1 0H 18N02S ([M+Hr) m/z 216.1053; measured m/z
MHz) ll 171.2, 139.2, 129.0 (2 carbons), 128.6 (2 carbons),
216.1043.
126.8, 46.4, 42.9, 30.3, 26.2; HRESI calculated for
CuH 1 6 N02Se ([M+Ht) m/z 274.0341; measured m/z
20 274.0339.
Example
(2S)-2-amino-4-(cyclohex-2-en-1-ylselanyl)butanoic
acid (compound 20-Se)
FIG. 13 with 3-bromo-cyclohexene yielded compound
20-Se (1.3 mg, 18% yield) as a white solid. 1 H NMR (D20,
400 MHz) Ii 5.64-5.72 (m, 2H), 3.90 (m, lH), 3.58-3.66 (m,
lH), 2.86 (t, l=l.00 Hz, lH), 2.52-2.68 (m, 2H), 2.05-2.20
(m, 2H), 1.90 (br. s, 2H), 1.50-1.70 (m, 3H); 13C NMR
(D20, 100 MHz) Ii 172.3, 131.4, 127.7, 53.4, 36.2, 31.5,
29.5, 24.2, 19.2, 17.6; HRESI calculated for C 10H 18 N02S
([M+Hr) m/z 264.0497; measured m/z 264.0508.
Example
(2S)-2-amino-4-[(3-azidopropyl)sulfanyl]butanoic
acid (compound 21)
FIG. 9 with dibromopropane (0.50 mL, 4.98 mmol)
yielded a mixture of dibromopropane:1-azido-3-bromopropane (2:5, 1.0 g). FIG. 10 with this mixture yielded com
pound 21 (1.7 mg, 25% yield) as a white solid together with
dimer compound 29 (1.0 mg, 10% yield) as a white solid.
Compound 21: 1H NMR (D20, 400 MHz) Ii 3.93 (t, 1=6.5
Hz, lH), 3.26 (t, 1=6.7 Hz, 2H), 2.54 (t, 1=7.6 Hz, 2H), 2.49
(t, 1=7.2 Hz, 2H), 1.93-2.14 (m, 2H), 1.70 (quin, 1=6.8 Hz,
2H); 13 C NMR (D20, 100 MHz) ll 172.3, 52.3, 49.7, 29.5,
27.69, 27.65, 26.3. HRESI calculated for C7H 1 5 N402S
([M+Hr) m/z 219.0910; measured m/z 219.0919.
Example

Example
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FIG. 9 with (E)-1,4-dibromobut-2-ene (2.0 g, 9.34 mmol)
yielded a mixture of (E)-1-azido-4-bromobut-2-ene:(E)-1,4dibromobut-2-ene (3:2, 2.31 g). FIG. 10 with this (E)-1azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture
yielded 23 (1.3 mg, 18% yield) as a white solid together with
dimer compound 30 (2.3 mg, 23% yield) as a white solid.
Compound 23: 1 H NMR (D20, 400 MHz) Ii 5.52-5.69 (m,
2H), 3.94 (t, 1=6.5 Hz, lH), 3.66 (d, 1=6.3 Hz, 2H), 3.09 (d,
1=6.7 Hz, 2H), 2.49 (t, 1=7.4 Hz, 2H), 1.92-2.12 (m, 2H);
13
C NMR (D20, 100 MHz) Ii 172.2, 130.9, 126.4, 52.1,
51.6, 31.7, 29.3, 24.9; HRESI calculated for C8H 1 5 N402S
([M+Hr) m/z 231.0910; measured m/z 231.0922.
Example
(2S)-2-amino-4-{ [(2E)-4-azidobut-2-en-1-yl]
selanyl}butanoic acid (compound 23-Se)

45
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(2S)-2-amino-4-(benzylsulfanyl)butanoic acid
(compound 22)
A protocol similar to that described for compound 3 using
L-Homocystine (250 mg, 0.93 mmol) and benzyl bromide
(0.13 mL, 1.12 mmol) was employed with slight modifica
tions. Specifically, after the evaporation of NH3 the dried
residue was dissolved in 15 mL ddH20 and the pH subsequently adjusted to 7 by adding 1 M HCI. A heavy precipi
tate formed, which was filtered and washed with cold ddH20
(3x10 mL). The filtrate was purified by recrystallization
from ethanol to provide compound 22 (0.15 g, 72% yield).
1
H NMR (D20/TFA=20/1, 400 MHz) Ii 7.08-7.19 (m, SH),
3.92 (t, 1=6.3 Hz, lH), 3.57 (s, 2H), 2.37 (t, 1=8.2 Hz, 2H),
1.84-2.04 (m, 2H); 13C NMR (D20, 100 MHz) Ii 171.3,

(2S)-2-amino-4-{ [(2E)-4-azidobut-2-en-1-yl]
sulfanyl}butanoic acid (compound 23)

55

FIG. 12 with the (E)-1-azido-4-bromobut-2-ene:(E)-1,4dibromobut-2-ene mixture in the synthesis of compound 23
yielded compound 23-Se (3.1 mg, 36% yield) as a white
solid. 1 H NMR (D20, 400 MHz) Ii 5.77-5.88 (m, lH),
5.42-5.51 (m, lH), 3.89 (t, 1=6.l Hz, lH), 3.44 (d, 1=6.7 Hz,
2H), 3.12 (d, 1=7.4 Hz, 2H), 2.41-2.50 (m, 2H), 2.07-2.10
(m, 2H); 13C NMR (D20, 100 MHz) ll 169.8, 134.2, 122.7,
53.2, 40.3, 30.5, 23.3, 16.8; HRESI calculated for
C8H 1 5 N402Se ([M+Hr) m/z 279.0355; measured m/z
279.0348.
Example
(2S)-2-amino-4-{ [(2E)-4-aminobut-2-en-1-yl]
selanyl}butanoic acid (compound 24-Se)

60
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(E)-1-azido-4-bromobut-2-ene was synthesized according
to the procedure reported by Islam et al.[29] (E)-1,4-dibro
mobut-2-ene (2 g, 9.34 mmol) was placed in a round-bottom
flask and dissolved in THF (10 mL). Sodium azide (800 mg,
12.2 mmol) was dissolved in 1 mL water and mixed the
solution of (E)-1,4-dibromobut-2-ene. The reaction was
stirred overnight at room temperature, diluted with diethyl
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ether (100 mL) and successively washed with water (15 mL)
and saturated NaCl solution (15 mL). The organic layer was
dried over anhydrous Na2 S04 and evaporated under reduced
pressure. Crude products were purified by flash silica gel
column chromatography using EtOAc/Hexanes affording
200 mg of (E)-1-azido-4-bromobut-2-ene (25% yield) and
320 mg of (E)-1,4-diazidobut-2-ene (25% yield), both as
colorless liquids. FIG. 13 with (E)-1-azido-4-bromobut-2ene yielded compound 24-Se (2.6 mg, 45% yield) as a white
solid. 1 H NMR (D20, 400 MHz) Ii 5.71-6.05 (m, lH),
5.37-5.59 (m, lH), 3.75 (t, 1=6.l Hz, lH), 3.45 (d, 1=6.7 Hz,
2H), 3.12 (d, 1=7.4 Hz, 2H), 2.37-2.45 (m, 2H), 2.01-2.07
(m, 2H); 1 3 C NMR (D20, 100 MHz) ll 173.2, 134.1, 122.8,
54.0, 40.4, 30.9, 23.3, 16.7; HRESI calculated for
C 3 H17N202 Se ([M+Ht) m/z 253.0450; measured m/z
253.0464.

40
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Example
10

15

Example
(2S)-2-amino-4-{[(4-methylphenyl)methyl]
sulfanyl}butanoic acid (compound 25)
FIG. 10 with 4-methylbenzyl bromide yielded compound
25 (2.0 mg, 27% yield) as a white solid. 1 H NMR (D20, 400
MHz) ll 7.05 (d, 1=8.0 Hz, 2H), 7.00 (d, 1=8.0 Hz, 2H), 3.93
(t, 1=6.3 Hz, lH), 3.53 (s, 2H), 2.36 (t, 1=7.4 Hz, 2H), 2.07
(s, 3H), 1.90-2.09 (m, 2H); 13 C NMR (D20, 100 MHz) Ii
171.3, 137.4, 134.9, 129.2 (2 carbons), 128.8 (2 carbons),
51.5, 34.3, 29.1, 25.6, 19.9; HRESI calculated for
C12H1 8N02 S ([M+Hr) m/z 240.1053; measured m/z
240.1061.
Example
(2S)-2-amino-4-{ [(2E)-3-phenylprop-2-en-1-yl]
sulfanyl}butanoic acid (compound 26)
FIG. 10 with 3-bromo-l-phenyl-1-propene yielded com
pound 26 (4.2 mg, 54% yield) as a white solid. 1H NMR
(D20, 400 MHz) ll 7.23 (d, 1=7.0 Hz, 2H), 7.13 (t, 1=7.4 Hz,
2H), 7.05 (dd, 1=14.5, 7.4 Hz, lH), 6.32 (d, 1=16.0 Hz, lH),
6.03 (dt, 1=16.0, 7.4 Hz, lH), 3.96 (t, 1=6.5 Hz, lH), 3.14 (d,
1=7.4 Hz, 2H), 2.44 (t, 1=7.4 Hz, 2H), 1.93-2.05 (m, 2H);
13
C NMR (D20, 100 MHz) Ii 171.3, 136.4 (2 carbons),
132.1, 128.7 (2 carbons), 126.2, 125.5, 110.0, 51.6, 32.8,
29.2, 24.9; HRESI calculated for C13 H1 8N02 S ([M+Hr)
m/z 252.1053; measured m/z 252.1075.

20

25

FIG. 11 with 4-nitrobenzyl bromide yielded compound 27
(3.6 mg, 18% yield) as a white solid. 1H NMR (D20, 400
MHz) Ii 8.06 (d, 1=9.0 Hz, 2H), 7.43 (d, 1=9.0 Hz, 2H), 3.94
(t, 1=6.5 Hz, lH), 3.75 (s, 2H), 2.45 (t, 1=7.0 Hz, 2H),
1.90-2.09 (m, 2H); 1 3 C NMR (D20, 100 MHz) Ii 171.7,
146.6, 129.7 (2 carbons), 123.8 (2 carbons), 117.6, 51.7,
34.2, 29.2, 25.8; HRESI calculated for C11H1 5N204 S ([M+
Hr) m/z 271.0747; measured m/z 271.0761.
Example
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FIG. 9 with dibromoethane (0.46 mL, 5.32 mmol) yielded
a mixture of dibromoethane:l-azido-2-bromoethane (1:2,
1.0 g). FIG. 10 with this dibromoethane:1-azido-2-bro
moethane mixture yielded compound 17 (2.1 mg, 33%) as a
white solid together with dimer compound 28 (4.2 mg, 46%)
as a white solid. Compound 28: 1 H NMR (D20, 400 MHz)
ll 3.95 (t, 1=6.3 Hz, 2H), 2.68 (s, 4H), 2.58 (t, 1=7.4 Hz, 4H),
1.94-2.15 (m, 4H); 13 C NMR (D20, 100 MHz) Ii 172.2 (2
carbons), 52.1 (2 carbons), 30.4 (2 carbons), 29.6 (2 car
bons), 26.3 (2 carbons); HRESI calculated for
C10 H21N204S2 ([M+Ht) m/z 297.0937; measured m/z
297.0949.

(2S)-2-amino-4-[(3-{[(3S)-3-amino-3-carboxypro
pyl] sulfany1}propyl)sulfanyl]butanoic acid (com
pound 29)
FIG. 9 with dibromopropane (0.50 mL, 4.98 mmol)
yielded a mixture of dibromopropane:1-azido-3-bromopro
pane (2:5, 1.0 g). FIG. 10 with this dibromopropane:l-azido3-bromopropane mixture yielded compound 21 (1.7 mg,
25% yield) as a white solid together with dimer compound
29 (1.0 mg, 10% yield) as a white solid. Compound 29: 1H
NMR (D20, 400 MHz) Ii 3.96 (t, 1=6.3 Hz, 2H), 2.56 (d,
1=7.6 Hz, 4H), 2.50 (d, 1=7.2 Hz, 4H), 1.96-2.12 (m, 4H),
1.71 (quin, 1=7.1 Hz, 2H); 1 3 C NMR (D20, 100 MHz) Ii
172.1 (2 carbons), 52.0 (2 carbons), 29.5 (2 carbons), 29.3
(2 carbons), 27.9, 26.2 (2 carbons). HRESI calculated for
C11 H23N204S2 ([M+Ht) m/z 311.1094; measured m/z
311.1101.
Example
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(2S)-2-amino-4-{ [(4-nitrophenyl)methyl]
selanyl}butanoic acid (compound 27-Se)
FIG. 13 with 4-nitrobenzyl bromide yielded compound
27-Se (1.6 mg, 18% yield) as a white solid. 1 H NMR (D20,

(2S)-2-amino-4-[(2-{[(3S)-3-amino-3-carboxypro
pyl]sulfanyl }ethyl)sulfanyl]butanoic acid (com
pound 28)

Example

Example
(2S)-2-amino-4-{ [(4-nitrophenyl)methyl]
sulfanyl}butanoic acid (compound 27)

400 MHz) Ii 8.05 (d, 1=9.0 Hz, 2H), 7.41 (d, 1=9.0 Hz, 2H),
3.88 (t, 1=6.4 Hz, lH), 3.83 (s, 2H), 2.47 (t, 1=6.8 Hz, 2H),
1.96-2.03 (m, 2H); 1 3 C NMR (D20, 100 MHz) Ii 171.9,
147.9, 146.2, 129.5 (2 carbons), 123.9 (2 carbons), 52.9,
30.5, 25.4, 17.7; HRESI calculated for C11H1 5N204SE
([M+Hr) m/z 319.0192; measured m/z 319.0201.

65

(2S)-2-amino-4-{[(2E)-4-{[(3S)-3-amino-3-carboxy
propyl]sulfanyl}but-2-en-1-yl] sulfanyl}butanoic
acid (Compound 30)
FIG. 9 with (E)-1,4-dibromobut-2-ene (2.0 g, 9.34 mmol)
yielded a mixture of (E)-1-azido-4-bromobut-2-ene:(E)-1,4dibromobut-2-ene (3:2, 2.31 g). FIG. 10 with this (E)-1azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture
yielded 23 (1.3 mg, 18% yield) as a white solid together with
dimer compound 30 (2.3 mg, 23% yield) as a white solid.
Compound 30: 1 H NMR (D20, 400 MHz) Ii 5.42-5.49 (m,
2H), 3.98 (t, 1=6.5 Hz, 2H), 3.02-3.10 (m, 4H), 2.48 (t, 1=7.4
Hz, 4H), 1.92-2.15 (m, 4H); 13 C NMR (D20, 100 MHz) Ii
171.9 (2 carbons), 128.9 (2 carbons), 51.9 (2 carbons), 31.8
(2 carbons), 29.2 (2 carbons), 25.0 (2 carbons); HRESI
calculated for C12H23N204 S2 ([M+Ht) m/z 323.1094; mea
sured m/z 323.1102.
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Gene cloning and protein expression and purification. The
Escherichia Coli MAT (eMAT) was amplified using colony
PCR from the cells of E. Coli BL21(DE3) strain using
primers
5

5' -ATACTGCATATGGCAAAACACCTTTTTACG

(forward, NdeI), per SEQ ID NO: 2, and
10

5' -CAGTATGGATCCTTACTTCAGACCGGCAGC

(reverse, BamHI), per SEQ ID NO: 3. The PCR products
were digested with respective restriction enzymes and
ligated into pET28a vector to provide expression plasmids
for proteins bearing N-terminal-His6 fusions. The expression
constructs for Homo Sapiens MATs (hMATs) were provided
by Prof. Chunming Liu. The Methanocaldococcus janna
schii MAT (mMAT) gene was synthesized (sequence pro
vided in SEQ ID NO: 1) by GenScript (Piscataway, N.J.)
with N-terminal NdeI and C-terminal EcoRI restriction sites
and subsequently also subcloned in the pE T28a vector to
provide an expression construct for the N-terminal-His6
fusion. Expression and purification of rebeccamycin meth
yltransferase, RebM was carried out as described in Zhang
et al.5a The E. coli S-adenosylhomocysteine nucleosidase
(EC 3.2.2.9) (also known as SAH hydrolase) gene was
amplified from the genome of E. coli BL21(DE3), using
primers

15

20

25
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5' -AGCCATATGA AAATCGGCATCATTGGTG

(forward, NdeI), per SEQ ID NO: 4, and
35

42

gradient of imidazole of 10-500 mM) using an AK TA
Purifier 10 (GE Healthcare). Buffer exchange of pooled
fractions containing the purified protein was accomplished
using a PD-10 colunm (GE Healthcare) eluted with 25 mM
Tris-HCI, 80 mM KC!, pH 8. Protein concentrations were
determined by Bradford assay (Bio-Rad, Hercules, Calif.,
USA) using BSA as a standard. For this study, all proteins
retained the N-terminal-His6 affinity tag.
MAT Assay
In vitro MAT reactions were conducted in a volume of 50
µI with 2 mM S/Se-alkylated analog (compounds 2-30), 1
mM ATP and 5 µM purified MAT in 25 mM Tris buffer pH
8.0, 5 mM MgCl2, 50 mM KC! for 4 h. The sMAT and
mMAT reactions were conducted at 65° C. while hMATs and
eMAT were incubated at 37° C. Reactions were quenched by
adding an equal volume of methanol followed by centrifu
gation (10,000xg for 15 min) to remove the precipitated
protein and product formation for each reaction was subse
quently analyzed by RP-HPLC using Method D (FIG. 15,
first column). For each reaction, percent yield was based
upon the integration of species at 254 nm and calculated by
dividing the integrated area of product and/or decomposed
product by the sum of integrated area of product and/or
decomposed product and the remaining substrate. The
assays were repeated twice under identical conditions, and
Table 2 (and FIG. 5) represents an average value of two
assays. The inclusion of adenine and 5'-R-thio-5'-adenosine
in these calculations is based upon the established SAM and
ATP chemical decomposition pathways which indicate
adenine and 5'-R-thio-5'-adenosine to only derive from
SAM (not ATP). All putative products were subsequently
confirmed by high resolution electrospray ionization (ESI)
mass spectra with positive (+) and/or negative (-) mode.

5' -ATAGA ATTCTTAGCCATGTGCAAGTTTCTG

(reverse, EcoRI), per SEQ ID NO: 5. The PCR products
were digested with respective restriction enzymes and
ligated into pET28a vector to provide expression plasmids
for the corresponding N-terminal-His6 fusion protein.
All five MATs with N-terminal-His6 (herein referred to
simply as hMATlA, hMAT2A, hMAT2, eMAT, and
mMAT), RebM and SAH hydrolase were expressed in a
corresponding E.coli BL21(DE3) host in the presence of 35
µg mL-1 of kanamycin at 37° C. to an OD 600 of -0.6,
induced with 0.5 mM IPTG, and continued to grow at 37° C.
for another 4 h. The cells were harvested by centrifugation
(30 min, 5000 rpm), resuspended in buffer A (20 mM
NaH2P04, 300 mM NaCl, 10 mM imidazole, pH 7.8). The
cells were lysed via incubation with 1 mg mL-1 lysozyme
(-50,000 U mg-1; Sigma-Aldrich, St. Louis, Mo., USA) for
30 min on ice followed by sonication (VirSonic 475; Virtis,
Gardiner, N.Y.; 100 W, 4x30 s pulses, -1 min between
pulses) on ice. MATs were purified via affinity chromatography (5 mL Hi Trap Ni-N TA chelating colunm, GE Health
care, Piscataway, N.J.) following standard linear gradient
(50 mM NaH2P04, 300 mM NaCl, pH 8.0 with a linear
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FIG. 18 illustrates the synthesis of (seleno)methionine
analogs, use of a high-throughput MAT assay, and product
verification via LC/MS.
Coupled hMAT2/RebM Assay
In vitro hMAT2-RebM coupled reactions were carried out
in a volume of 25 µI with 2 mM S/Se-alkylated analogs, 1
mM ATP, 50 µM rebeccamycin ortholog compound 31
(synthesized as previously described), [30] 5 µM hMAT2, 10
µM RebM, 5 µM SAH hydrolase in 25 mM Tris buffer pH
8.0, 5 mM MgCl2, 50 mM KC! for 24 h at 37° C. Reactions
were quenched by adding an equal volume of methanol
followed by centrifugation (10,000 g for 15 min) to remove
the precipitated protein and the product formation for each
reaction was subsequently analyzed by RP-HPLC using
Method E (FIG. 15, middle column). The assays were
repeated twice under identical conditions and Table 2 (and
FIG. 8) represents an average value of two assays. The
reactions were scaled (>500 µM compound 31), purified by
semi-prep HPLC using Method E and the putative new
products were confirmed by NMR ( Table 3) and HRMS.
TABLE 3

NMR Chemical Shifts (in PPM) of 4'0-R-Rebeccamycin in CD30D; where R �
Atom

-H

-----CH3

-----CH2CH3 -----CH2CHCH2

-----CH2 CCH

-----CH2CCN

Cl'/Hl'
C2'/H2'
C3'/H3'

86.2/6.20
74.5/3.83
78.3/3.74

86.2/6.20
74.6/3.83
78.2/3.83

86.2/6.20
74.4/3.82
78.2/3.82

86.2/6.20
74.9/3.82
78.6/3.89

86.2/6.20
74.8/3.82
78.3/3.95

86.2/6.20
74.8/3.81
78.3/3.87
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NMR Chemical Shifts (in PPM) of 4'0-R-Rebeccamycin in CD30D; where R �
Atom

-H

C4'/H4'
C5'/H5'
C6'/H6',
H6"
4-0'-H3
4-0'---CH2 CH3

69.0/4.26
80.3/3.99
59.8/4.25,
4.03
NA
NA

78.8.0/3.98
79.2/3.99
59.9/4.13,
4.03
61.1/3.79[a]
NA

4-0'---CH2 CHCH2

NA

NA

77.0/4.07
79.2/3.99
59.9/4.13,
4.03
NA
(69.5/4.09,
3.96)
(15.9/1.33)
NA

4-0'---CH2 CCH

NA

NA

4-0'---CH2 CCN

NA

NA

77.0/4.14
79.2/4.05
60.0/4.15,
4.05
NA
NA

76.8/4.21
79.2/4.05
60.2/4.24,
4.04
NA
NA

78.0/4.26
78.73/4.12
60.1/4.17,
4.06
NA
NA

NA

NA

NA

(74.9/4.59,
4.44) (6.10)
(5.39,
5.22) [a].[b]
NA

NA

NA

(61.0/4.70,
NA
4.63) (2.92jlc]
NA
(58.3/4.85)[a]

[alresonances listed as Cl"/Hl", C2"/H2", C3"/H3" in sequential order;
[b]Bc C2"(CH) and C3" (CH2) were not observed in tbe HSQC;
[c]Bc C3" (CH) was not observed in the HSQC.

Example II
The MAT from Sulfolobus solfataricus (sMAT), an
enzyme from a poorly explored class ofthe MAT family, has
the ability to produce a range of differentially alkylated
SAM analogs in the presence of non-native methionine
analogs and ATP. To investigate the molecular basis for
SAM analog production, the sMAT in the SAM bound,
S-adenosylethionine (SAE) bound, and unbound forms was
crystallized. Notably, among these structures, the SAE
bound form offers the first MAT structure containing a
non-native product and cumulatively, these structures add
new structural insight into the MAT family and allow for
detailed active site comparison with its homologs in E. coli
and humans. As the only existing thermostable MAT struc
tures from archaea, the structures herein also provide as a
basis for future engineering to broaden SAM analog pro
duction as reagents for methyltransferase-catalyzed 'alkylrandomization' and/or the study of methylation in the con
text of biological processes.
Some members of the MAT family accommodate non
native methionine analogs [9, 55] and, in the context of
coupled reactions containing permissive methyltransferases,
enable the ability for natural product 'alkylrandomization'.
A sequence divergent class ofMATs has been identified in
archaea [37, 47], with only -20% sequence identity with E.
coli and human MATs. However, structural information and
broad substrate specificity assessment for members of this
divergent class of MATs is lacking. The present disclosure
provides Sulfolobus solfataricus MAT (sMAT) to enable the
cumulative synthesis of a broad panel of unnatural SAM
analogs (31 analogs detected) starting from synthetic S/Se
alkylated Met analogs (42 analogs) or commercial sources
(3 analogs).
Interestingly, in contrast to its low sequence similarity to
other MATs, sMAT displays the typical three-domain fold
and partly conserved active site architecture. Unlike other
known MAT structures, the activity of sMAT cannot be
stimulated by ionic potassium [47]. This can be supported
structurally by the presence of a lysine side chain (K63) in
sMAT, which likely has a similar function to potassium ion
in other MATs. Further, the capture of the first atypical
ligand bound structure of MAT provides insights on the
nature of sMAT broad substrate specificity and a template
for expanding the substrate scope. The present disclosure

25

30

35

40

45

50

55

60

65

expose sMAT as an efficient catalyst for SAM analog
production that is amendable to downstream SAM-utilizing
processes.
Overall Structural Organization:
The crystal structures of sMAT have been determined
successfully at 2.19 A or 2.39 A resolution for the SAM
liganded form, 2.49 A for the SAE-liganded form and 2.21
A for the unliganded form. Similar to E. coli MAT (eMAT)
[52], Rat liver MAT (r!MAT) [35], human MATs (hMATlA
and hMAT2A) [49], sMAT packs as a tetramer. All four
sMAT structures contain two subunits, A and B, in the
asymmetric unit and the tetramer is formed by a 2-fold
crystallographic symmetry axis. The buried surface interface
between the two subunits A and B, and the two dimers AB
and CD are calculated to be 2570 and 1870 A2 respectively
[41]. In the tetramer, there are four potential ligand-binding
sites: two sites sandwiched by A and B, and the other two
sites between C and D. Compared with other known MAT
structures [43], the sMAT monomer adopts a similar 3-do
main architecture with secondary structure variants. Inter
estingly, unlike other MATs, structural variations were
observed between subunits A and B in sMAT with an
average root mean square deviation (rmsd) of 0.51 A in both
the liganded and unliganded structures. In addition, the
maximum rmsd between all the A subunits and the maxi
mum rmsd between all the B subunits in all sMAT structures
are calculated as 0.29 A and 0.21 A, respectively. As a result,
half of the active sites are in a more open conformation.
Active Site Contents:
The MAT catalyzed SAM formation occurs via a sequen
tial two-step mechanism. In the first step, SAM is formed by
a direct SN2 reaction, in which the sulfur atom of methionine
attacks the CS' position of ATP and thus cleaves the poly
phosphate chain from ATP. In the second step, the triphos
phate is further hydrolysed to diphosphate (PPi) and phos
phate (Pi)[43]. Komoto et al. identified two critical residues,
lysine 165 and histidine 14, in eMAT for this proposed SN2
reaction based on their ligand-bound structures. Interest
ingly, even with significant sequential variations to eMAT
and other MATs, several conserved residues were observed
in sMAT, mainly located around the active site, including the
two crucial residues, lysine (K201) and histidine (H29) for
the proposed SN2 reaction.
The interaction between sMAT and products in the active
site are multifaceted. The adenine ring of SAM is recognized
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by a hydrogen bond with the side chain ofaspartate 144 and
a stacking interaction with the aromatic ring of tyrosine 270.
Several water molecules surrounding by the adenine ring
also form a hydrogen bond network to the enzyme. The
2'-0H and 3'-0H of the adenosine ribose interact with the
side chains of aspartate 199, aspartate 282 and serine 277.
Similar interactions involving aspartic acids have been seen
in other MAT structures bound with SAM, but not for serine
[40, 50]. The methionine/ethionine moiety (of SAM and
SAE, respectively) forms hydrogen bonds with four resi
dues, in which the amino group interacts with the side chain
ofaspartate 282, and the carboxylate group interacts with the
side chain ofhistidine 58, asparagine 60 and asparagine 159.
The methyl or ethyl group is buried in a slightly hydrophobic
pocket surrounded by asparagine 159, aspartate 160, isoleu
cine 349, leucine 145 and the adenine ring. As similar
observations in eMAT [40], the PPi and Pi formed a
U-shaped conformation with two magnesium ions closely
stacked on both sides. Further, the two magnesium sites are
formed with the side chains of aspartate 31, glutamate 305
and three water molecules. The phosphate groups are sur
rounded and stabilized by the side chains of several basic
amino acids: lysine 25, histidine 29, lysine 201, arginine 288
and lysine 310.
As described, the ligands are solvent inaccessible and
thus, the entrance of the active site requires a dynamic and
flexible region. A flexible loop region was previously iden
tified as the gate for the active site in MATs [53]. This gate
loop feature has been confirmed by crystal structures of
eMAT, hMAT2A and hMAT2B, in which the loop becomes
ordered when ligands are bound and it becomes disordered
when the active site is empty [40, 50]. A similar gating loop
region was identified in sMAT, which has interactions with
the adenine ring and the methionine or ethionine moiety.
Unusual Product Formation During Crystallization: Two
sets of ligand bound crystals were obtained in the presence
of 5 mM ADP, 10 mM ethionine (or methionine), 10 mM
Mg2+ ion, and 1.4 M NaHPOiK2HP04. Thus based on the
simulated annealing Fo-Fc omit map of the active site, one
ADP, one P04, two Mg2+ and one ethionine (or methionine)
molecule were initially built in. However, this model does
not fit the electron density perfectly, because the Fo-Fc omit
map does not agree with the placement ofthe crucial carbon
atom. Thus, it is very clear that the product has already
formed and a model including PPi and SAE (or SAM) is
more appropriate. The new model has a lower temperature
factor and a better real-space correlation to electron density
in the active site. MAT-catalyzed SAM/SAE formation via
ADP and Met/Eth has not been previously observed. In
addition, incubation of sMAT in the presence of ADP and
methionine at 65 ° C. for 4 hr under standard assay condi
tions led to no detectable product. Thus, two explanations
for this unusual product formation have been proposed: (i)
The sMAT protein is contaminated by ATP during expres
sion or purification; (ii) The unusual reaction catalyzed by
sMAT can actually occur in vitro, but may take as long as
one month to finish, which corresponds to the length of
crystal growth in this experiment.
Structure Homology:
A DALI search [38] for structures similar to the sMAT
monomer returned several hits, all of which are previously
solved MAT structures with Z-scores between 23 and 29.
Those MAT structures share a very high level of overall
sequence identity (>50%) and a high level of conservation
among residues associated with substrates binding. Interestingly, sMAT only has a maximum sequence identity of19%
with these known MATs, but shares a similar three-domain.
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For the comparison of active site residues, crystal struc
tures of sMAT, eMAT [40] and hMAT2A [49] were aligned
by ligands as described in the methods section. Surprisingly,
16 of 17 active site residues detected in sMAT have an
identical or similar residue in eMAT and hMAT2A. The only
extra residue sMAT has is H315 , which forms hydrogen
bond with 05 in di-phosphate. DALI-based sequence align
ment was able to identify 11 pairs ofresidues. Eight ofthem
are conserved among sMAT and other MATs, including the
crucial residues histidine and lysine for the proposed SN2like mechanism [40]. The other three pairs are very similar
residues at the same spot: for example, in sMAT tyrosine 270
forms stacking interactions with the adenine ring of SAE/
SAM, while in eMAT it is phenylalanine 230. Intriguingly,
there are another 5 pairs of residues that are not detectable
via DALI search: the side chain of sMAT lysine 25 (eMAT
lysine 245) helps stabilize the tri-phosphate group; the side
chains of sMAT histidine 58 and asparagine 60 (eMAT
glutamine 98 and lysine 269) form hydrogen bonds with the
carboxyl group ofmethionine or ethionine; the side chain of
sMAT glutamate 305 (eMAT aspartate 271) form ionic
bonds with the magnesium ion; the side chain of sMAT
lysine 63 occupies the same spot as the eMAT potassium ion
and helps stabilize the di-phosphate ligand.
Unlike other known MATs, it has been previously
reported that the activity ofsMAT cannot be enhanced by K+
[47]. In the present study, all the crystals of sMAT were
obtained from the crystallization condition containing more
than 150 mM potassium, but electron density suitable for K+
was not observed in any datasets. Combined with the active
sites alignment evidence, it is very likely that the catalytic
activity ofsMAT is not affected by K+, because the lysine in
sMAT serves to present the requisite cation properties.
Substrate Specificity of sMAT:
The substrate specificity for sMAT based upon RP-HPLC
is illustrated in FIG. 16 wherein observed 5'-methyl-thio
(seleno)-5'-deoxyadenosine (M TA) production (via
RP-HPLC) was interpreted as product based upon the wellestablished SAM decay pathways indicating M TA to
directly derive from SAM (not ATP). [18, 11, 57] Of the 45
putative substrates tested with sMAT, 11 led to appreciable
(>50%) SAM analog production, an additional 15 led to
moderate (25-50%) conversion, while 5 offered detectable
product ( <25%) under the conditions described. In general,
smaller alkyl substitutions were better tolerated, suggesting
steric infringement to possibly prohibit larger substitutions.
Interestingly, in the case where direct comparisons could be
made, the degree ofunsaturation correlated with a reduction
in turnover (e.g., propyl>allyl>propargyl). Importantly,
notable turnover was observed with branched analogs (FIG.
16) that previously led to only trace product with MATs
studied to date.
A comparison of the kinetic parameters for L-methionine
and the non-native substrate for which a ligand-bound
structure is available (L-ethionine) reveals that the profi
ciency ofthe sMAT increases for both the substrates with an
increase in temperature from 37 ° C. to 65 ° C., and correlates
to both an increase in kcat and a decrease in Km. At either
temperature, the kcat values for the sMAT reaction with
L-methionine or L-ethionine are similar and the reduced
proficiency with L-ethionine when compared to the native
substrate L-methionine derive from a combination ofhigher
Km values for both L-ethionine and ATP.
Interestingly, eMAT and hMAT2A also have some ability
to incorporate ethionine. The ethionine turns over with
sMAT, and hMAT2A is near 100%, whereas eMAT is just
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10%. A ligand-based alignment shows that sMAT has a
0.15-0.2 mM sMAT and 25 mM Tris pH 8.0. For sMAT:
larger cavity around the ethyl/methyl group than either
(SAM) condition, the protein solution contains 0.15-0.2 mM
hMAT2A or eMAT.
sMAT, 1 mM SAM and 25 mM Tris pH 8.0. For sMAT:
Also, branched analogs highlighted in FIG. 16 turnover
(ADP+Met/Eth), the protein solution contained 0.2-0.3 mM
significantly better with sMAT, comparing with eMAT, 5 sMAT, 5 mM ADP, 10 mM Met (or Eth), 10 mM MgCl2,
hMAT2A and mMAT (MAT from Methanocaldococcus jan
12.5 mM KC!, 7.5 mM D T T and 25 mM Tris pH 8. All
naschii). Interestingly, mMAT is a thermophilic archaea
crystals were cryoprotected by 25% DMSO or 25% ethylene
MAT that has all active site residues conserved with sMAT.
glycol and flash frozen in liquid nitrogen.
However, further comparison between their active site cavi
X-ray diffraction data were collected at the Life Science
ties cannot be conducted, because mMAT structure remains 1
° Collaborative Access Team (LS-CAT) with an X-ray wave
unknown. The current structural information suggests the
length of 0.98 A for all sMAT crystals at the Advanced
better turnover rate of branched SAM analogs with sMAT is
Photon Source at Argonne National Laboratory. Datasets
possibly mediated by some general orientation/dynamics of
were
indexed and scaled by HKL2000 or XDS [39, 46]. For
the gating loop and/or secondary shell variations.
Conclusions: sMAT has the characteristic fold and the 15 structure solution of apo sMAT, phenix.HySS was used for
determination of selenium atom sub-structure, AutoSol for
typical tetramer assembly of known MATs. In addition, the
phasing and phenix.autobuild for model building (Adams et
slightly expanded substrate scope of sMAT over other MATs
al., 2010). For the other structures of sMAT with ligands,
studied to date highlight sMAT as a useful tool for the
molecular replacement was utilized using the apo sMAT
production of SAM analogs. In conjunction with the dem
onstration of coupled MAT-methyltransferase systems for 20 structure as a starting model. The structures including sev
eral double conformations were manually rebuilt in several
differential alkylation, this chemoenzymatic strategy cir
rounds by Coot [33] and further refined by phenix.refine
cumvents a major liability in the use of synthetic SAM
analogs-namely, the dramatic instability of the SAM ana
[31]. Mo!Probity was used to validate the quality of the
logs.
coordinates [32]. All structural figures in this paper were
Further, the elucidation of the active site architecture with 25 generated using PyMOL [48].
the atypical product bound, the characterization of the gating
Ligand-based Structural alignment of MAT homologs: In
loop region, as well as the sMAT turnover reactions with
order to best compare the active site contents between
different SAM analogs provide a blueprint for future SAM
structures with low sequence identity, four structures were
analog production.
30 aligned based on ligand positions by PyMOL. They are
Materials and Methods
eMAT with SAM and PPNP (PDB code 1RG9) [40],
Expression and Purification of sMAT:
The methionine adenosyltransferase (MAT) gene (Uni
hMAT2A with SAM (PDB code 2P02) [49], sMAT with
Prot accession: Q980S9) was cloned into NdeI/EcoRI-di
SAM, PPi and P04 (PDB code 4KOB) and sMAT with SAE,
gested pE T28a to enable production of recombinant N-Hisc
PPi
and P04 (4L2Z). 1RG9, 2P02 and 4KOB were first
sMAT). For protein production, the corresponding pE T28a 35
aligned by SAM molecule, and thus 4L2Z was aligned to
sMAT construct was transformed into the E. coli methionine
4KOB via several active site residues. Atom clashes were
auxotroph strain 8834 (DE3) and auto-induction media
(Sreenath et al., 2005) was used for expression at 37° C. The
calculated in presence of hydrogen atoms using PyMOL and
cells were harvested by centrifugation at 5000 rpm for 30
displayed as bumps.
min and resuspended in buffer 20 mM NaH 2P04, 300 mM 40
In-vitro sMAT assay: In vitro sMAT reactions were con
NaCl, 10 mM imidazole pH 7.8. The cells were lysed via
ducted in a volume of 50 µI with 2 mM S/Se-alkylated
lysozyme incubation followed by sonication on ice. Subse
quently, N-His6-sMAT was purified via Ni-NTA chelating
analog, 1 mM ATP and 5 µM purified sMAT in 25 mM Tris
colunm (GE Healthcare) following a protocol with a linear
buffer pH 8.0, 5 mM MgCl2, 50 mM KC! for 4 h at 65° C.
imidazole (10-500 mM) elution gradient (50 mM NaH2P04, 45 Reactions were quenched by adding an equal volume of
300 mM NaCl, pH 8.0) The Hisctag was removed by
methanol followed by centrifugation (10,000xg for 15 min)
thrombin (Novagen) cleavage and the affinity tag was
to remove the precipitated protein and product formation for
removed via a second round of Ni-NTA affinity chromatog
raphy. After the buffer exchange using PD-10 colunm (25
each reaction was subsequently analyzed by reverse phase
mM Tris-HCI, pH 8), the desired truncated Se-sMAT was 50 HPLC (RP-HPLC) using method described below. For each
concentrated to 27 mg/mL, flash frozen in liquid nitrogen
reaction, percent yield was based upon the integration of
and stored at -80° C. Protein concentrations were deter
species at 254 nm and calculated by dividing the integrated
mined by Bradford assay (Bio-Rad, Hercules, Calif., USA)
area of product and/or decomposed product by the sum of
using BSA as a standard. Unless otherwise indicated, the
term sMAT herein refers to SeMet-labeled sMAT after 55 integrated area of product and/or decomposed product and
thrombin cleavage.
the remaining substrate. The assays were repeated twice
Crystallization, Diffraction, and Structure Determination:
under identical conditions, and Table 4 (and FIG. 17)
General screens were performed with PEGRx H T, Crystal
represents an average value of two assays. The inclusion of
Screen H T, Index H T, and SaltRx HT (Hampton Research)
utilizing a Mosquito® dispenser ( T TP lab Tech) by the 60 adenine and 5'-R-thio-5'-adenosine in these calculations is
sitting drop method. Crystal growth was monitored by
based upon the established SAM and ATP chemical decom
Bruker Nonius Crystal Farms at 20° C. All sMAT crystals
position pathways which indicate adenine and 5'-R-thio-5'
with or without substrates were obtained by mixing 2 µL of
adenosine to only derive from SAM (not ATP). All putative
protein solution and 2 µL of reservoir solution, 1.40 M
sodium phosphate monobasic monohydrate/potassium phos 65 products were subsequently confirmed by high resolution
electrospray ionization (ESI) mass spectra with positive (+)
phate dibasic pH 5.6, using the sitting drop method. For
unbound sMAT crystals, the protein solution contained
and/or negative ( -) mode.
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TABLE 4
Surnrn

Analog

of sMAT reactions
Percentage Turn-Over Theoretical mass

NH2

50
Observed mass

100

399.1445, 297.0896[a] 399.1444, 298.0965[b]

100

447.0890, 345_034o[a] 447.0895, 346.0416[b]

HOOC�S/
NH2
HOOC�Sr("'

Is�
/Se�
Is�
/s,�

84

413.1602, 311.1052[a]

413.1599, 312.1121[b]

76

461.1046, 359.0497[a]

416.1040, 360.0565[b]

36

321.0896[a]

322.1051 [b]

28

369.0340[a]

370.0411 [b]

NA

NA

68

322.0848[a]

323.0919[b]

12

370.0293[a]

371.0371 [b]

27

425.1602, 323.1052[a]

425.1609, 324.1129[b]

30

371.0497[a]

372.0568[b]

44

427.1758, 325.1209[a]

427.1759, 326.1281[b]

66

475.1203, 373.0653[a]

475.1200, 374.0720[b]

53

427.1758, 325.1209[a]

427.1762, 326.1282[b]

40

373.0653[a]

374_0743[b]

ND

/s�c
/"
�

Is�

N

Is�
/Se�
Is �
/Se�
Is �
/Se�
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TABLE 4-continued
Surnrn
Analog

Is�

of sMAT reactions

Percentage Turn-Over Theoretlcal mass

Observed mass

30

437.1602, 335.1052[a]

437.1599, 336.1124[b]

10

383.0497[a]

384.0566[b]

27

439.1758, 337.1209[a]

439 · 1754, 338.1275[b]

15

439.1758, 337.1209[a]

439 · 1754, 338.1282[b]

46

385.0653[a]

386.0730[b]

27

441.1915, 339.1365[a]

441 · 1966, 340.1477[b]

70

489.1359, 387.0810[aJ

489 · 1358, 388.0882[b]

57

441.1915, 339.1365[a]

441 · 1918, 340.1439[b]

ND

NA

NA

ND

NA

NA

14

451.1758

451.1756

50

454.1616, 352.1066[a]

454.1615, 353.1140[b]

36

455.2071, 353.1522[a]

455· 2123, 354.1634[b]

12

453.1915

453.2044

/s
�

'"'
!st
'(

Is�
/Se�

Is l
/S�NH2

/Se�NH2

Is�
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TABLE 4-continued
Surnrn
Analog

of sMAT reactions
Percentage Turn-Over Theoretical mass

Observed mass

44

399.0810[aJ

400.0878[b]

ND

NA

NA

ND

NA

NA

60

468.1772, 366.1223[a]

468.1772, 367.1296[b]

ND

NA

NA

ND

NA

NA

28

480.1772, 378.1223[a]

480.1768, 379.1292[b]

1
N3
�
Se

24

426.0667[a]

427.0687[b]

�
1
NH2
Se

38

400.0762[a]

401.0830[b]

ND

NA

NA

ND

NA

NA

ND

NA

NA

/Se�

/S D
/s.D
/S
� N3

ls
v

/

s,
v

ls

�

N3

/s
�

/

s
�

/

s
�
No,
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TABLE 4-continued
Summ
Analog

of sMAT reactions
Percentage Turn-Over Theoretical mass

Observed mass

ND

NA

NA

ND

NA

NA

ND

NA

NA

ND

NA

NA

;
(�NO,
(� s '/',(OOH
;

NH2
NH2

/S�S�COOH

[a]theoretical mass of degraded 5'-alkyl-thio(seleno)-5'-deoxyadenosine (MTA); observed mass of degraded 5'-alkyl thio(seleno)-5'-deoxyadenosine (MTA):
[bl[M+H];
NDnot detected;
NAnot applicable.

RP-HPLC method: Reactions were quenched by the addi
tion of equal volume of methanol followed by centrifugation
at 10,000 g for 15 min to remove precipitated protein before
applying on an analytical Varian ProStar HPLC [Luna C 18
column, 5 µm, 4.6 mmx250 mm; Phenomenex, Torrance,
Calif., USA; gradient of 10% B to 40% B over 15 min, 40%
B to 75% B over 5 min (A= lO mM NaH2P04, 5 mM octane
sulfonic acid, pH was adjusted to 3.5 using phosphoric acid;
B=acetonitrile) flow rate=1 mL min- 1; A254]. Reaction products were confirmed by HRMS.
Kinetic Measurements of sMAT Reactions: Pseudo first
order kinetics was assessed in triplicate under saturating
ATP (2.5 mM) and variable L-methionine/L-ethionine
(0.007, 0.013, 0.033, 0.066, 0.133, 0.333, 0.66, 1.33 mM)
and saturating L-methionine/L-ethionine (2.5 mM) and vari
able ATP (0.013, 0.033, 0.066, 0.133, 0.333, 0.66, 1.33 mM)
concentrations. Reactions were performed in buffer contain
ing 25 mM Tris pH 8.0, 40 mM KC! and 5 mM MgCl2, and
0.5 µg purified sMAT was added and incubated at 37° C. or
65 ° C. in a final volume of 20 µL. Reaction products were
analyzed using RP-HPLC method above and product quan
tification was carried out using standard curve generated by
commercial SAM. The kinetic curves were fit to the Michae!is-Menton equation using Prism software.
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-continued

-continued

AAGGAAAAGAATGAAGTCATCAAGCTGCCGGTGGGTACCACGGCAGTTAA

GGTTAATCACGTCGGCAAGATTTATAACATCCTGGCGAATCTGATTGCCA

AGCAGCCAAGGAATATCTGAAAAAGGTCCTGCGTAACGTTGATGTCGACA

ACGATATCGCAAAACTGGAAGGTGTCAAGGAATGTTACGTGCGTATTCTG

AAGATGTTATTATCGATTGCCGCATTGGTCAGGGCAGCATGGACCTGGTG

TCACAAATCGGCAAACCGATTAATGAACCGAAGGCCCTGGATATCGAAAT

GATGTTTTTGAACGCCAGAAAAACGAAGTGCCGCTGGCTAACGACACGAG

TATCACCGAAGACTCGTACGATATTAAAGACATCGAACCGAAAGCTAAGG

TTTCGGTGTTGGCTACGCGCCGCTGTCCACCACGGAACGTCTGGTGCTGG
AAACCGAACGTTTTCTGAACAGCGATGAACTGAAAAACGAAATCCCGGCG

10

GTTGGTGAAGACATTAAAGTCATGGGTCTGCGTGAAGGCAAAAAGATTAC

15

AAAAAGATCGCTGACGGCTATGAAGTTGAAATCCACATTAACACGGCCGA

ATTACCCCGTTCCGTCCGATGAGTATGGAAGCAGCTTCCGGTAAAAACCC

5'-ATACTGCATATGGCAAAACACCTTTTTACG

(forward, Ndel).
SEQ ID NO: 2 is

TGACTATGAACGCGAATCCGTGTACCTGACCGTTACGGGTACCAGCGCAG
AAATGGGTGATGACGGCTCTGTGGGTCGTGGCAACCGCGTTAATGGCCTG

GTCGAAGGCAAGGTCACCACGTTTTGAGAATTC-3'

SEQ ID NO: 2 is

CCTGACGATCGCGATGGCCGTGGTTGATCGCTATGTGAAGAACATCGAAG
AATACAAAGAAGTGATCGAAAAGGTTCGTAAAAAGGTCGAAGATCTGGCA

AAATTGCGAACAAATGGCTGGACAACATTATGGAAGTTCAGAAGATGATC

20

5'-CAGTATGGATCCTTACTTCAGACCGGCAGC

(reverse, BamHI).

SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

5

SEQ ID NO 1
LENGTH, 1230
TYPE, DNA
ORGANISM, Methanocaldococcus jannaschii

<400> SEQUENCE, 1

catatgcgta atatcattgt gaaaaaactg gatgtggaac cgattgaaga acgcccgacg

60

gaaattgttg aacgtaaagg tctgggtcat ccggattcaa tttgcgacgg tatcgccgaa

120

agcgtgtctc gcgcactgtg taaaatgtac atggaaaagt ttggcacgat tctgcatcac

180

aataccgatc aggtcgaact ggtgggcggt catgcttatc cgaagtttgg cggtggcgtc

240

atggtgtcac cgatttacat cctgctgtcg ggtcgtgcaa ccatggaaat cctggataag

300

gaaaagaatg aagtcatcaa gctgccggtg ggtaccacgg cagttaaagc agccaaggaa

360

tatctgaaaa aggtcctgcg taacgttgat gtcgacaaag atgttattat cgattgccgc

420

attggtcagg gcagcatgga cctggtggat gtttttgaac gccagaaaaa cgaagtgccg

480

ctggctaacg acacgagttt cggtgttggc tacgcgccgc tgtccaccac ggaacgtctg

540

gtgctggaaa ccgaacgttt tctgaacagc gatgaactga aaaacgaaat cccggcggtt

600

ggtgaagaca ttaaagtcat gggtctgcgt gaaggcaaaa agattaccct gacgatcgcg

660

atggccgtgg ttgatcgcta tgtgaagaac atcgaagaat acaaagaagt gatcgaaaag

720

gttcgtaaaa aggtcgaaga tctggcaaaa aagatcgctg acggctatga agttgaaatc

780

cacattaaca cggccgatga ctatgaacgc gaatccgtgt acctgaccgt tacgggtacc

840

agcgcagaaa tgggtgatga cggctctgtg ggtcgtggca accgcgttaa tggcctgatt

900

accccgttcc gtccgatgag tatggaagca gcttccggta aaaacccggt taatcacgtc

960

ggcaagattt ataacatcct ggcgaatctg attgccaacg atatcgcaaa actggaaggt

1020

gtcaaggaat gttacgtgcg tattctgtca caaatcggca aaccgattaa tgaaccgaag

1080

gccctggata tcgaaattat caccgaagac tcgtacgata ttaaagacat cgaaccgaaa

1140

gctaaggaaa ttgcgaacaa atggctggac aacattatgg aagttcagaa gatgatcgtc

1200
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-continued

gaaggcaagg tcaccacgtt ttgagaattc

1230

<210> SEQ ID NO 2
<211> LENGTH, 30
<212> TYPE, DNA

<213> ORGANISM: Neisseria denitrificans

<400> SEQUENCE, 2
30

atactgcata tggcaaaaca cctttttacg

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 30
TYPE, DNA
ORGANISM, Bacillus amyloliquefaciens

<400> SEQUENCE, 3
cagtatggat ccttacttca gaccggcagc

30

<210> SEQ ID NO 4
<211> LENGTH, 28
<212> TYPE, DNA

<213> ORGANISM: Neisseria denitrificans

<400> SEQUENCE, 4
agccatatga aaatcggcat cattggtg
<210>
<211>
<212>
<213>

28

SEQ ID NO 5
LENGTH, 30
TYPE, DNA
ORGANISM, Excherichia coli

<400> SEQUENCE, 5
atagaattct tagccatgtg caagtttctg

30

What is claimed is:
1. An S-adenosyl-L-methionine (SAM) or Se-adenosylL-methionine (SeAM) analog of the Formula III:

-continued
40

�NH,

·

(III)
45

50

wherein X is selected from the group consisting of S and
Se;
wherein, when X is S, R1 is selected from the group
consisting of:
� �
N,
\'c�,
,

\lYy·�·

·
\'y

�

60

;

�·�·�·
N

55

N

�

�

;

�
.

�.�.,
�NO,;�,,

65

wherein, when X 1s Se, R1 1s selected from the group
consisting of:
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S
COOH,
� �
NH2
�H2

�S�COOH,

and

10

15

4. An S-adenosyl-L-methionine (SAM) analog of the
formula:

20

2. A compound of the Formula II:

25

(II)
30

wherein R1 is selected from the group consisting of

35

/x� S �COOH

40

NH2
NH2
/

X�S�COOH,

and

45

/X� S �COOH

NH2

50

5. A method of producing an S-adenosyl-L-methionine
analog according to claim 4, comprising the step of reacting
a first substrate comprising methionine-tetrazole with a
second substrate comprising adenosine triphosphate (ATP)
in the presence of a methionine adenosyltransferase (MAT).
6. The method of claim 5, wherein the MAT comprises at
least one of human MAT II catalytic alpha and regulatory
beta subunit (hMAT2), human MAT II catalytic alpha sub
unit alone (hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol
fataricus MAT (sMAT), and Methanocaldococcus janna
schii MAT (mMAT).
7. A method of producing the S-adenosyl-L-methionine
analog of claim 1, comprising the step of reacting a first
substrate comprising a methionine analog with a second
substrate comprising adenosine triphosphate (ATP) in the
presence of a methionine adenosyltransferase (MAT).
8. The method of claim 7, wherein the MAT comprises at
least one of human MAT II catalytic alpha and regulatory
beta subunit (hMAT2), human MAT II catalytic alpha subunit alone (hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol
fataricus MAT (sMAT), and Methanocaldococcus janna
schii MAT (mMAT).
9. The method of claim 7, wherein the first substrate is of
the Formula II:

and Xis S.
3. An S-adenosyl-L-methionine analog of the Formula III:

(II)
55

(III)

wherein R1 is selected from the group consisting of

wherein X is S and R1 is selected from the group con
sisting of:

65
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-continued

(II)

Ix� !x�!x�
N,

,

,

!x�, !x�,
!s�.

5
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wherein X is S.
10. A method of producing the Se-adenosy 1-L-methionine
analog of claim 1, comprising the step of reacting a first
substrate comprising a methionine analog with a second
substrate comprising adenosine triphosphate (ATP) in the
presence of a methionine adenosyltransferase (MAT).
11. The method of claim 10, wherein the first substrate is
of the Formula II:
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wherein X is Se.
12. A method of producing an indolocarbazole analog,
comprising the step of reacting a first substrate comprising
a methionine analog with a second substrate in the presence
of a methionine adenosyltransferase (MAT), wherein the
methionine analog is of the Formula II:
(II)
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wherein R1 is selected from the group consisting of
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wherein X is selected from the group consisting of S and
Se; and
wherein the second substrate comprises at least one
indolocarbazole group.
13. The method of claim 12, wherein the MAT comprises
at least one of human MAT II catalytic alpha and regulatory
beta subunit (hMAT2), human MAT II catalytic alpha sub
unit alone (hMAT2A), human MAT I catalytic subunit alpha
(hMATlA), Escherichia coli MAT (eMAT), Sulfolobus sol
fataricus MAT (sMAT), and Methanocaldococcus janna
schii MAT (mMAT).
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